Article

Cell

Mitochondrial Fission Promotes the Continued Clearance of Apoptotic Cells by Macrophages

Graphical Abstract



Authors

Ying Wang, Manikandan Subramanian, Arif Yurdagul, Jr., ..., Masatoshi Nomura, Frederick R. Maxfield, Ira Tabas

Correspondence

iat1@columbia.edu

In Brief

How are dead cells in our bodies rapidly cleared by phagocytes in order to avoid inflammation and necrosis?

Highlights

- Continued efferocytosis requires Drp1-mediated mitochondrial fission
- Mitochondrial fission allows release of ER Ca²⁺ into the cytoplasm
- Ca²⁺-mediated vesicular trafficking enables phagocytosis of a second apoptotic cell
- Mice lacking myeloid Drp1 have defective efferocytosis and its pathologic sequelae



Article

Mitochondrial Fission Promotes the Continued Clearance of Apoptotic Cells by Macrophages

Ying Wang,^{1,7} Manikandan Subramanian,^{1,2,7} Arif Yurdagul, Jr.,^{1,7} Valéria C. Barbosa-Lorenzi,³ Bishuang Cai,¹ Jaime de Juan-Sanz,³ Timothy A. Ryan,³ Masatoshi Nomura,⁴ Frederick R. Maxfield,³ and Ira Tabas^{1,5,6,8,*}

¹Department of Medicine, Columbia University, New York, NY 10032, USA

³Department of Biochemistry, Weill Cornell Medical College, New York, NY 10065, USA

⁴Department of Medicine and Bioregulatory Science, Kyushu University, Fukuoka, Japan

⁵Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA

⁶Department of Physiology, Columbia University, New York, NY 10032, USA

⁷These authors contributed equally

⁸Lead Contact

*Correspondence: iat1@columbia.edu

http://dx.doi.org/10.1016/j.cell.2017.08.041

SUMMARY

Clearance of apoptotic cells (ACs) by phagocytes (efferocytosis) prevents post-apoptotic necrosis and dampens inflammation. Defective efferocytosis drives important diseases, including atherosclerosis. For efficient efferocytosis, phagocytes must be able to internalize multiple ACs. We show here that uptake of multiple ACs by macrophages requires dynaminrelated protein 1 (Drp1)-mediated mitochondrial fission, which is triggered by AC uptake. When mitochondrial fission is disabled, AC-induced increase in cytosolic calcium is blunted owing to mitochondrial calcium sequestration, and calcium-dependent phagosome formation around secondarily encountered ACs is impaired. These defects can be corrected by silencing the mitochondrial calcium uniporter (MCU). Mice lacking myeloid Drp1 showed defective efferocytosis and its pathologic consequences in the thymus after dexamethasone treatment and in advanced atherosclerotic lesions in fat-fed Ldlr^{-/-} mice. Thus, mitochondrial fission in response to AC uptake is a critical process that enables macrophages to clear multiple ACs and to avoid the pathologic consequences of defective efferocytosis in vivo.

INTRODUCTION

Phagocytic clearance of apoptotic cells (ACs), or efferocytosis, is a critical process in normal physiology that prevents necrosis of dead cells and triggers anti-inflammatory and pro-resolving responses in phagocytes (Vandivier et al., 2006; Arandjelovic and Ravichandran, 2015). Efferocytosis can become defective in certain pathologic settings, e.g., autoimmune disease and atherosclerosis, where it promotes disease progression (Vandivier et al., 2006; Arandjelovic and Ravichandran, 2015; Khanna

et al., 2010; Thorp and Tabas, 2009). Efferocytosis involves recognition of ACs by cell receptors and then phagocytosis and phagolysosomal digestion of the ACs (Hochreiter-Hufford and Ravichandran, 2013). While there has been great progress in understanding these processes, much less is known about the mechanisms that enable phagocytes to internalize multiple ACs over relatively short periods of time. In settings where cell death is rampant, the high ratio of ACs to phagocytes demands multiple, rapid AC uptake by individual phagocytes, which raises two key questions: (1) what regulates cellular membrane recycling to allow new phagosome formation after a previous round of phagocytosis (Aderem, 2002); and (2) how do phagocytes process the metabolic cargo of multiple ACs (Han and Ravichandran, 2011).

While investigating these areas, we made the surprising observation that AC uptake by macrophages triggers a mitochondrial fission response that was associated with and dependent on a marked increase in the mitochondrial fission protein dynamin-related protein 1 (Drp1) (Chan, 2012; Ishihara et al., 2009). Most importantly, when mitochondrial fission was prevented in macrophages exposed to a first round of ACs, subsequent AC uptake was compromised. Moreover, mice with compromised mitochondrial fission in myeloid cells showed evidence of defective efferocytosis and its pathologic conseguences in vivo. Mechanistic studies revealed that mitochondrial fission enables efficient AC corpse degradation in phagolysosomes as well as calcium-dependent vesicular trafficking, both of which are required for continued AC phagocytosis. These studies reveal a critical series of intracellular reactions during efferocytosis that facilitate multiple AC uptake and demonstrate the importance of this process in clearance of ACs in vivo.

RESULTS

Interaction of Macrophages with Apoptotic Cells Leads to an Increase in Drp1-Mediated Mitochondrial Fission

When macrophages are incubated with ACs, some of the macrophages take up the ACs (AC⁺) and some do not (AC⁻). We observed that the mitochondria were shorter and more

²CSIR-Institute of Genomics and Integrative Biology, New Delhi 110025, India



Figure 1. Interaction of Macrophages with Apoptotic Cells Triggers Drp1-Mediated Mitochondrial Fission

(A) Bone-marrow-derived macrophages were incubated with PKH67-labeled apoptotic Jurkat cells (green) and MitoTracker Red FM (red) for 45 min at a 5:1 AC:macrophage ratio. Macrophages that had or had not engulfed an AC (AC⁺, AC⁻) were visualized by confocal microscopy. Asterisks show examples of elongated mitochondria, and arrowheads show clusters of small mitochondria. Bar, 2 μ m. Mean mitochondrial length was measured in 0.5- μ m z sections (n = 4 biologic replicates with ten or more cells quantified per group).

(B) Immunoblot of Drp1 and β -actin of lysates of macrophages incubated without or with ACs for 45 min. The bar graph shows densitometric quantification of immunoblots normalized to β -actin (n = 3 biological replicates).

fragmented in AC⁺ versus AC⁻ macrophages (Figure 1A), which was accompanied by an increase in the mitochondrial fission protein Drp1 both in the cytoplasm and mitochondria (Figures 1B and 1C). The source of the increased Drp1 was the phagocyte, not the AC, because the Drp1 increase was similar when phagocytes were exposed to Drp1-deficient ACs versus control ACs, i.e., apoptotic macrophages from Drp1^{fl/fl} Lysmcre+/-(Cre^{+/-}) versus control Cre^{-/-} mice (Ishihara et al., 2009) (Figures S1A and S1B-S1E confirms Drp1 deficiency in Cre^{+/-} macrophages). The increase in Drp1 in macrophages exposed to ACs was not observed at the mRNA level (Figure S2F) and was not blocked by actinomycin D but was inhibited by cycloheximide, indicating post-transcriptional regulation (Figure S1G). To determine whether Drp1 was causally important in ACinduced mitochondrial fission, we treated macrophages with MDIVI-1, a selective inhibitor of Drp1 (Cassidy-Stone et al., 2008), or used macrophages from the aforementioned Cre+/mice. In both cases, mitochondrial length was increased and, most importantly, not decreased in response to AC uptake (Figure 1D). Thus, efferocytosis triggers Drp1-induced mitochondrial fission in macrophages exposed to ACs.

Mitochondrial Fission-Defective Macrophages Have a Defect in High-Burden Efferocytosis

To explore the functional significance of these findings, we compared the interaction of $Cre^{-/-}$ and $Cre^{+/-}$ macrophages with Calcein AM-labeled ACs. At relatively early time points or low AC:macrophage ratios, AC association with Cre^{-/-} and Cre+/- macrophages appeared similar, but this was decreased in Cre^{+/-} macrophages at longer time points or higher AC:macrophage ratios (Figure 2A). These results were confirmed by flow cytometry using PKH67-labeled macrophages and CypHer5E-labeled ACs, which become fluorescent in acidic phagolysosomes (Figure S1H). Similar defects in efferocytosis were seen in MDIVI-1-treated mouse macrophages (Figure S1I) and in human monocyte-derived macrophages transfected with Drp1 small interfering RNA (siRNA) (Figure 2B). Loss of Drp1 did not affect macrophage differentiation or polarization in response to lipolysaccharide (LPS) + interferon (IFN)-y or interleukin-4 (IL-4) (Figures S2A-S2C).

Based on these data, we hypothesized that mitochondrial fission enabled macrophages to internalize multiple ACs ("high-burden efferocytosis"). To test this hypothesis, we conducted a two-stage efferocytosis experiment in which macrophages were first incubated for 45 min with ACs labeled with PKH67 (green) and then, after AC removal and a 120-min interval, incubated with a second round of ACs labeled with PKH26 (red). Consistent with the hypothesis, the percentage of macrophages that had internalized both labels was significantly less in MDIVI-1-treated or Cre^{+/-} macrophages than in control cells

(Figure 2C). As designed, MDIVI-1 increased mitochondrial length in macrophages with two ACs to a level approaching that of macrophages with no ACs (Figure S2D). Note that MDIVI-1 did not further decrease second AC uptake when added to Cre^{+/-} macrophages (Figure S2E), as expected for an ontarget effect of the inhibitor.

We next asked whether the defect in second AC uptake was due to a decrease in AC binding or AC internalization. For this purpose, the actin polymerization inhibitor cytochalasin D was added after the first round to block second AC internalization, i.e., to assay second AC binding. The data show that second AC binding was similar between $\text{Cre}^{-/-}$ and $\text{Cre}^{+/-}$ macrophages (Figure 2D), indicating that the decrease in second AC efferocytosis in Drp1-deficient macrophages was due to a defect in AC internalization.

To verify that the above data were due to effects on mitochondrial fission rather than some other effect of Drp1, we silenced mitochondrial fission factor (Mff) (Otera et al., 2010) and confirmed that it impaired mitochondrial fission in AC⁺ macrophages (Figure S3A). As with Drp1 depletion, Mff silencing decreased second AC uptake (Figure S3B). Further, silencing the *fusion* mediator Mfn1 resulted in hyper-fragmented mitochondria and *enhanced* efferocytosis (Figures S3C–S3E) at a 10:1 AC:macrophage ratio. These combined data indicate that mitochondrial fission per se enables efficient high-burden efferocytosis.

Mitochondrial Fission-Defective Macrophages Have a Defect in Phagosome Sealing

Although efferocytosis of a first-encountered AC appeared normal in mitochondrial fission-deficient macrophages, a subtle defect in phagosomal sealing could have escaped detection. To test for this possibility, we incubated wild-type (WT) or Drp1-deficient macrophages with ACs that were both PKH67-labeled and biotinylated. After 15, 30, or 60 min, unbound ACs were removed and the macrophages were fixed. Alexa-Fluor-568-labeled streptavidin (SA-AF568) was then added to the cells, and macrophage AF568 labeling was quantified. This method distinguishes fully internalized from partially engulfed ACs, as fully engulfed ACs are not accessible to SA-AF568. We found that there was a higher fraction of AF568-labeled ACs in Drp1-deficient (Cre^{+/-}) versus Cre^{-/-} control macrophages at 30 and 60 min, indicating a defect in phagosome sealing (Figure 3A). Similar results were found in macrophages in which Mff was silenced (Figure S3F).

We reasoned that a defect in phagosome sealing would cause a delay in acidification of AC-containing phagosomes (Lu and Zhou, 2012). To test this prediction, we incubated $Cre^{-/-}$ and $Cre^{+/-}$ macrophages with CypHer5E-labeled ACs and then recorded the time interval from initial AC-macrophage interaction to CypHer5E-positivity using live-cell fluorescence microscopic imaging. The data show a clear defect in time to CypHer5E-positivity

⁽C) Immunoblot of the indicated proteins in mitochondrial and cytosolic fractions of macrophages incubated without or with ACs for 45 min. The bar graph shows densitometric quantification of Drp1 expression in the mitochondrial fraction normalized to VDAC1 (n = 3 biological replicates).

⁽D) Macrophages from control $Drp1^{fl/fl}$ Lysmcre^{-/-} mice (Cre^{-/-}), either untreated or treated with 10 μ M MDIVI-1, and macrophages from $Drp1^{fl/fl}$ Lysmcre^{+/-} mice (Cre^{+/-}) mice were incubated with PKH67-labeled ACs (green) and MitoTracker Red FM (red) and analyzed as in (A) (n = 3 with \geq 30 cells quantified per group). Asterisks show examples of elongated mitochondria, and arrowheads show clusters of small mitochondria. Bar, 2 μ m.

For all panels, values are mean ± SEM; *[#]p < 0.05; n.s., not significant. For (D), *difference from the two other AC⁻ groups; [#]difference from AC⁻ Veh Cre^{-/-} and from the two other AC⁺ groups.



Figure 2. Drp1-Deficient Macrophages Have a Defect in High-Burden Efferocytosis

(A) $Cre^{-/-}$ or $Cre^{+/-}$ macrophages were incubated with Calcein AM-labeled ACs at various times at a 10:1 AC:macrophage ratio or at various ratios for 1 hr. Efferocytosis was quantified as the total percentage of macrophages that were positive for PKH67-labeled ACs (n = 3 biological replicates, using the average of technical duplicates for each).

(B) Similar to (A), except human monocyte-derived macrophages transfected with either scrambled RNA (ScrRNA) or Drp1 siRNA were used. Immunoblot for Drp1 is shown.

(C) Vehicle- and MDIVI-1-treated $Cre^{-/-}$ macrophages or vehicle-treated $Cre^{+/-}$ macrophages were incubated with PKH67-labeled ACs at a ratio of 5:1 ACs:macrophages for 45 min. The ACs were removed, and then, after a 120-min interval, the macrophages were incubated with PKH26-labeled ACs at a ratio of 5:1 for 45 min. The unengulfed ACs were removed, and the percentage of PKH26⁺ PKH67⁺ macrophages of PKH67⁺ macrophages was analyzed by epifluorescence microscopy (n = 4 biological replicates).

(D) As in (C), except the macrophages were treated with 5 μ M cytochalasin D 30 min before the addition of the second AC (n = 3 biological replicates, using the average of technical duplicates for each).

For all panels, values are mean ± SEM; *p < 0.05; n.s., not significant.

in Cre^{+/-} versus Cre^{-/-} macrophages (Figures 3B and S3G), consistent with a delay in acidification of AC-containing phagosomes. In contrast, there was no defect in *lysosomal* acidification

in Cre^{+/-} macrophages (Figure S3H). These combined data indicate that Drp1-deficient macrophages have a defect in phagosome sealing around newly encountered ACs.



Cr

+/--/-+/--/-+/-

30'

60

15'

Figure 3. Drp1-Deficient Macrophages Have a Defect in Phagosome Sealing

(A) Cre^{-/-} and Cre^{+/-} macrophages were incubated with biotinylated and PKH67-labeled ACs at a ratio of 10:1 ACs:macrophages for either 15, 30, or 60 min. Unengulfed ACs were then removed. The cells were then fixed in 2% paraformaldehyde, incubated with streptavidin-Alexa Fluor 568 (SA-AF568) for 30 min, and viewed by fluorescence microscopy. Representative PKH67, AF568, and merge images are shown: the fourth column shows a bright-field image taken from the merge series. Bar, 20 $\mu m.$ The percentage of PKH67^+ macrophages not stained (sealed) or stained (unsealed) with AF568 was quantified (n = 3 biological replicates, using the average of technical duplicates for each).

(B) Cre^{-/-} and Cre^{+/-} macrophages were incubated with CypHer5E and Hoechst-labeled apoptotic polymorphonuclear leukocytes (PMNs) for 30 min at 4°C to allow AC binding but not internalization. Unbound ACs were removed by rinsing, fresh warm medium was added, and timelapse fluorescence microscopic imaging was conducted. The graph shows the average time for the CypHer5E fluorescence to appear (n = 4 sets of analyses).

(C) Cre^{-/-} and Cre^{+/-} macrophages were incubated for 45 min with PKH67-labeled ACs at a ratio of 10:1 ACs:macrophages. Unengulfed ACs were removed, and then, after a 120-min interval, macrophages were incubated with a second round of biotinylated and fluorescently labeled ACs for either 15, 30, or 60 min, followed by analysis for sealing as in (A).

For all panels, values are mean \pm SEM; *p < 0.05.

To investigate the potential relevance of this finding to other types of phagocytosis, we assayed phagosome sealing in macrophages exposed to 10-µm latex beads, which are similar in size to the apoptotic Jurkat cells used in our assays. $\mathrm{Cre}^{+\!/-}$ macrophages showed a defect in phagosome sealing around these latex beads, similar to the situation with ACs (Figure S3I, graph 1). Phagocytosis processes can differ depending on size of cargo (Kubota et al., 1983). We therefore examined phagocytic sealing in macrophages exposed to 4-µm latex beads and similarly sized immunoglobulin G (IgG)-opsonized sheep red blood cells (IgGsRBCs). As a control for the IgG-sRBCs, we also tested larger sized IgG-coated Jurkat cells. In contrast to what we saw with 10-µm beads, and now shown as well for IgG-coated Jurkat cells (Figure S3I, graph 4), plasma membrane sealing around the smaller beads and sRBCs was similar in Cre^{-/-} and Cre^{+/-} macrophages (Figure S3I, graphs 2 and 3). Thus, the sealing defect in Drp1-deficient macrophages is specific to larger particles. Finally, to determine whether Cre^{+/-} macrophages have defective sealing around a secondarily encountered AC, we used biotinylated second ACs in the two-stage AC assay described in the previous section. SA-AF568 accessibility was greater in the Cre^{+/-} cells, indicating a sealing defect around the second AC in Drp1-deficient

Cre+/-

Cre-/-

macrophages (Figure 3C). In summary, mitochondrial fission is necessary for proper phagosome sealing during efferocytosis. This defect causes a subtle defect in efferocytosis when macrophages interact with a first AC and likely contributes to the more marked defect in efferocytosis when the phagocytes encounter additional ACs, as explained in the following sections.

Drp1-Deficient Macrophages Have a Defect in LC3-Associated Phagocytic Degradation of AC Corpses

In those Drp1-deficient macrophages that had successfully internalized an AC, we observed that there was less fragmentation of the labeled AC corpse compared with control macrophages, suggesting defective corpse degradation. To quantify corpse degradation, we incubated Cre^{-/-} and Cre^{+/-} macrophages for 45 min with PKH26-labeled ACs. After rinsing away unbound ACs, we then counted the percentage of AC⁺ macrophages that showed non-fragmented PKH26 staining over the ensuing 3 hr. Confirming our subjective observations, the percentage of macrophages with non-fragmented ACs was greater in $\operatorname{Cre}^{+/-}$ versus $\operatorname{Cre}^{-/-}$ macrophages (Figure 4A). Moreover, in a time-lapse fluorescence microscopy experiment, we observed that the first time point at which the internalized CypHer5E ACs



Figure 4. Drp1-Deficient Macrophages Have a Defect in LAP and AC Corpse Degradation

(A) $Cre^{-/-}$ and $Cre^{+/-}$ macrophages were incubated for 45 min with PKH26-labeled ACs. Unengulfed ACs were removed, and the macrophages were incubated for another 3 hr. Cells were fixed with 2% formaldehyde, and AC fragmentation was quantified as the percentage of macrophages that showed fragmented PKH26 fluorescence (n = 3 biological replicates, using the average of technical duplicates for each). Bar, 20 μ m.

showed evidence of fragmentation was significantly delayed in $\rm Cre^{+/-}$ versus $\rm Cre^{-/-}$ macrophages (Figure S4A).

To explain this observation, we considered whether preventing mitochondrial fission leads to defective LC3-associated phagocytosis (LAP), a process by which LC3-II conjugation to phagosomes enables phagosome-lysosome fusion and AC corpse degradation (Martinez et al., 2011; Martinez et al., 2016). To test this idea, $Cre^{-/-}$ and $Cre^{+/-}$ macrophages were incubated with CellVue Claret-labeled ACs for 1 hr. After removal of non-attached ACs, the macrophages were fixed, treated with digitonin to remove non-membrane-bound LC3, and immunostained for LC3. Fluorescence microscopic imaging showed the expected decoration of corpse-containing phagosomes with LC3 in control macrophages (Martinez et al., 2011), while this feature appeared markedly decreased in Drp1-deficient macrophages (Figure 4B, images). Furthermore, Cre^{+/-} macrophages had decreased membrane-bound LC3 as quantified by flow cytometry (Figure 4B, graph). Importantly, Drp1 deficiency did not reduce the number of LC3 punctae in macrophages treated with rapamycin, which induces a different LC3-mediated process, macroautophagy (Blommaart et al., 1995) (Figure S4B).

When macrophages encounter ACs, lysosomal NADPH oxidase-mediated reactive oxygen species (ROS) is elevated, which is necessary for LC3 conjugation to maturing phagosomes, phagolysosomal fusion, and AC corpse degradation (Martinez et al., 2015). To determine whether ROS of AC-containing phagosomes was decreased in Cre^{+/-} macrophages, we incubated Cre^{-/-} and Cre^{+/-} macrophages with ACs labeled with the ROS probe 2',7'-dichlorofluorescin diacetate (H2 DCFDA). Cre^{+/-} macrophages showed a 40% decrease in H₂ DCFDA fluorescence compared with Cre^{-/-} macrophages (Figure 4C). To determine whether this decrease in ROS was functionally relevant, we increased the ROS in phagosomes in $\mathrm{Cre}^{+\!/-}$ macrophages by incubating the cells with ACs loaded with the oxidant tert-butyl hydroperoxide (TBHP), which restored ROS in Cre^{+/-} macrophages (Figure S4C). This manipulation increased membrane-bound LC3 conjugation, corpse degradation, and high-burden efferocytosis (Figures 4D-4F). Thus, the defect in LAP-mediated corpse degradation in Drp1-deficient macrophages can be linked to a defect in phagosomal ROS.

The Defects in Phagosome Sealing and Corpse Degradation in Drp1-Deficient Macrophages Are Linked to Mitochondrial Calcium Uniporter-Mediated Mitochondrial Calcium Sequestration

In exploring how a defect in mitochondrial fission might be linked to defective efferocytosis, we first considered that mitochondrial fission was required for sufficient ATP production. However, ATP levels in macrophages were similar in control and Drp1-deficient macrophages under both basal conditions and after the addition of ACs (Figure S4D). We next considered the role of cytoplasmic calcium because (1) cytoplasmic calcium is increased when macrophages encounter ACs, and this process is necessary for efficient AC clearance (Cuttell et al., 2008; Gronski et al., 2009); and (2) in certain settings, cytosolic calcium is decreased by direct transfer of endoplasmic reticulum (ER) calcium to fused mitochondria (de Brito and Scorrano, 2008; Maltecca et al., 2012; Luchsinger et al., 2016). We therefore hypothesized that defective mitochondrial fission impairs AC-induced increase in cytosolic calcium, i.e., via excessive mitochondrial calcium sequestration, which then contributes to defective efferocytosis.

We first determined whether Drp1 deficiency altered cytosolic calcium levels induced by AC exposure. Cre^{-/-} and Cre^{+/-} macrophages were transduced with a lentivirus encoding the cytosolic calcium indicator GCaMP6f (Cyto-GCaMP6f) (Chen et al., 2013), followed by incubation with CellVue Claret-labeled ACs. As expected, GCaMP6f fluorescence remained at basal levels in both Cre^{-/-} and Cre^{+/-} AC⁻ macrophages, but there was a significant decrease in GCaMP6f fluorescence in AC+ Cre+/-M ϕ s versus AC⁺ Cre^{-/-} M ϕ s (Figures 5A and S4E). Conversely, mitochondrial calcium, which was assayed in macrophages transduced the mitochondrial calcium indicator 2x-COX8-GCaMP6f (Mito-GCaMP6f), was higher in AC⁺ Cre^{+/-} versus AC⁺ Cre^{-/-} macrophages (Figures 5B and S4F). Finally, ER calcium was assayed in macrophages transduced with ER-GCaMP6f-150 (de Juan-Sanz et al., 2017). As predicted (Cuttell et al., 2008; Gronski et al., 2009), ACs led to an early decrease in ER calcium. However, the overall pattern was similar between AC⁺ Cre^{-/-} and Cre^{+/-} macrophages (Figure S4G), which is consistent with Drp1 deficiency causing a change in distribution of ER-released calcium, i.e., mitochondrial versus cvtosol, but not a change in ER calcium release itself.

Because calcium facilitates vesicular membrane transport from lysosomes to developing phagosomes (Czibener et al., 2006), a defect in this process could contribute to the phagosome sealing defect and its consequences in Drp1-deficient macrophages. In support of this idea, we found that the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA)-acetoxymethyl ester (AM) reduced plasma membrane sealing and membrane-bound LC3 (LAP) in Cre^{-/-} macrophages (Figures 5C and S5A). Conversely, adding the calcium ionophore ionomycin to Cre^{+/-} macrophages restored plasma

⁽B) $Cre^{-/-}$ and $Cre^{+/-}$ macrophages were incubated with PKH26-labeled ACs (red) for 45 min and then fixed in 4% formaldehyde for 15 min, incubated with 50 µg/mL digitonin for 5 min, and immunostained for LC3 (green). Some of the cells were viewed by confocal fluorescence microscopy (two examples of 0.5-µm z-step images from each group are shown), and others were detached and analyzed by flow cytometry for membrane-bound LC3 mean fluorescence intensity (MFI) in AC⁺ macrophages (n = 3 biological replicates). Bar, 5 µm; arrowhead in each of the Cre^{-/-} images depicts a ring of LC3 immunostain surrounding an AC-containing phagosome, which was not seen in any of the z-steps of the Cre^{+/-} images.

⁽C) $Cre^{-/-}$ and $Cre^{+/-}$ macrophages were incubated for 1 hr with ACs that were labeled with the ROS-sensitive dye, H₂DCFDA, or vehicle control. The macrophages were detached and analyzed by flow cytometry for H₂DCFDA fluorescence (n = 3 biological replicates).

⁽D and E) Cre^{-/-} and Cre^{+/-} macrophages were incubated for 45 min with ACs loaded with the oxidant TBHP (50 μ M). Analysis and quantification for membranebound LC3 (D) and corpse degradation (E) were conducted as in (B) and (A), respectively (n = 3–4 biological replicates).

⁽F) Two-stage efferocytosis was quantified as in Figure 2C using first-round PKH67-labeled ACs that were loaded with TBHP (n = 4 biological replicates). For all panels, values are mean \pm SEM; *p < 0.05.





(A and B) $Cre^{-/-}$ and $Cre^{+/-}$ macrophages were transduced Cyto-GCaMP6f (A) or Mito-GCaMP6f (B) and then incubated with CellVue Claret-labeled ACs. Confocal microscopy was used to capture time-lapse images every 5 min, with measurements beginning when an AC fell into the plane of focus of a macrophage in the case of AC+ cells (t = 0). Data are presented as fold increase in mean GCaMP6f fluorescence intensity (MFI)/cell divided by MFI/cell at time 0 (n = 3 cells for AC⁻ macrophages and n = 7–12 cells for AC⁺ macrophages, with two plates of cells examined for each condition). membrane sealing and membrane-bound LC3 to the control levels (Figures 5D and S5B).

The uptake of ER calcium by mitochondria is mediated by the mitochondrial calcium uniporter (MCU) (Drago et al., 2012). We therefore asked whether silencing of MCU could prevent the phagosome sealing defect observed in Cre^{+/-} macrophages. We found that transfecting Cre^{+/-} macrophages with siRNA targeting MCU, which resulted in a marked decrease in MCU protein, partially restored both AC-induced cytosolic calcium levels and phagosome sealing (Figures 5E and 5F). Note that loss of Drp1 did not increase MCU expression (Figure S5C). Furthermore, MCU silencing was unable to restore AC-induced mitochondrial fission in Cre^{+/-} macrophages (Figure S5D), indicating that MCU functions downstream of fission. These data suggest that preventing mitochondrial fission lowers AC-induced cytosolic calcium increase owing to MCU-mediated mitochondrial calcium sequestration. This impairment in the cytosolic calcium response then contributes to defective phagosome sealing around the AC.

Finally, we questioned whether the MCU-mediated blunting of AC-induced cytosolic calcium increase in AC⁺ Drp1-deficient macrophages was linked to the defects in phagolysosomal ROS, LAP-mediated corpse degradation, and high-burden efferocytosis. With regard to ROS, a previous study showed that mitochondrial calcium sequestration decreased activation of the enzyme that generates lysosomal ROS, NADPH oxidase (Dikalov et al., 2012). We found that silencing MCU in Cre^{+/-} macrophages restored phagolysosomal ROS, membranebound LC3, AC fragmentation, and second AC uptake to levels approaching those in Cre^{-/-} macrophages (Figures 5G–5J). Thus, MCU-mediated mitochondrial calcium sequestration in Drp1-deficient macrophages plays a central role in defective efferocytosis in these cells.

The Decrease in AC-Induced Increment in Cytosolic Calcium in Drp1-Deficient Macrophages Causes a Defect in the Translocation of Intracellular Membranes to the Cell Surface

We reasoned that defective calcium regulation in fission-defective macrophages might not only impair vesicle trafficking-mediated sealing around a first AC, but also limit the recycling of phagolysosomal membranes to the cell surface for new phagosome formation around a subsequently encountered AC (Muller et al., 1983). To address this hypothesis, we determined whether there was a defect in intracellular membrane trafficking to the cell surface in Cre^{+/-} macrophages that had internalized a first AC. We conducted time-lapse confocal microscopy of macrophages that were first incubated for 60 min with the amphiphilic styryl fluorescent dye FM1-84 to label endocytic membranes (Ryan et al., 1996) and then incubated with CypHer5E-labeled ACs. Because FM1-84 rapidly desorbs from membrane, delivery of labeled membranes back to the plasma membrane results in loss of fluorescence, which can be measured as the rate and extent of fluorescence decay (Ryan et al., 1996). In view of our previous finding that Cre^{+/-} macrophages show delayed acidification, we synchronized our measurements such that time 0 was the appearance of the CypHer5E signal for each individual Cre^{-/-} and Cre^{+/-} macrophage.

As an initial observation, we found that much of the FM1-84 label co-localized with the AC-containing phagosome, which likely reflects intracellular transfer of label from endocytic recycling membranes to the membranes of the newly internalized phagosome and its AC content. In Cre-/- macrophages that did not internalize an AC, the overall intensity and pattern of the FM1-84 label did not change over the 24-min observation period (Figure 6A, upper-left set of images and black line in graph). In contrast, Cre^{-/-} macrophages that had internalized an AC showed somewhat diminished FM1-84 labeling after 24 min, reflecting transport to the plasma membrane (Ryan et al., 1996) (Figure 6A, upper-right set of images and blue line in graph). Most importantly, while the overall FM1-84 labeling pattern at time 0 in Cre+/- macrophages appeared similar to that in Cre^{-/-} macrophages, the intensity and pattern of the label did not decrease over time in the Cre^{+/-} cells (Figure 6A, lowerleft set of images and red line in graph). Moreover, when MCU was silenced in $\mathrm{Cre}^{\scriptscriptstyle +\!/-}$ macrophages to correct the defect in cytosolic calcium, the loss of FM1-84 label now equaled that in Cre^{-/-} macrophages (Figure 6A, lower-right set of images and green line in graph). These combined data suggest that Drp1deficient macrophages have a defect in recycling of corpse-containing phagolysosomal membranes owing to mitochondrial sequestration of calcium.

Degradation of Phagolysosomal Cargo Is Necessary for Efficient Uptake of Subsequently Encountered ACs

We questioned whether there was a link between impaired AC corpse degradation and defective high-burden efferocytosis in Drp1-deficient macrophages. We began by asking whether

(E) Cytosolic calcium was assessed using Cyto-GCaMP6f-transduced macrophages as in (A), except the macrophages were also treated with *Mcu* siRNA or scrambled RNA (ScrRNA) control (n = 4–8 cells, with two plates of cells examined for each condition). Also shown is an immunoblot of MCU.

(G) Phagosomal H₂DCFDA mean fluorescence intensity (MFI) was quantified by flow cytometry as in Figure 4C in $Cr^{-/-}$ and $Cre^{+/-}$ macrophages transfected with scrambled RNA or *Mcu* siRNA (n = 3 biological replicates).

(H-J) Cre^{-/-} and Cre^{+/-} macrophages transfected with scrambled RNA or *Mcu* siRNA were assayed for membrane-bound LC3 MFI (H) as in Figure 4C; the percentage of macrophages with non-fragmented ACs (I) as in Figure 4A; and two-stage efferocytosis (J) as in Figure 2C (n = 3–4 biological replicates).

For all panels, values are mean \pm SEM. For (A), *p < 0.05 for the AC⁺ Cre^{-/-} group relative to the other three groups. For (B), *p < 0.05 for the AC⁺ Cre^{+/-} group relative to the other three groups. For (E), *p < 0.05 for the scrambled RNA Cre^{-/-} groups relative to the scrambled RNA Cre^{+/-} group, and [#]p < 0.05 for the *AC*⁺ Cre^{+/-} group. For (C) and (G)–(J), *p < 0.05. For (D), values marked by different symbols are p < 0.05 relative to each other and to the Cre^{-/-} value. For (F), values marked by different symbols are p < 0.05 relative to each other and to the Cre^{-/-} value. For (F), values marked by different symbols are p < 0.05 relative to each other and to the Cre^{-/-} value within each time group.

⁽C and D) $Cre^{-/-}$ macrophages were incubated with 5 μ M BAPTA-AM (C), or $Cre^{-/-}$ and $Cre^{+/-}$ macrophages were incubated with 2 μ M ionomycin (lono) or vehicle control (Veh) (D). Phagosome sealing was assayed 45 min after incubation with ACs as in Figure 3 (n = 4 biological replicates).

⁽F) Time course of phagosome sealing was conducted as in Figure 3 in Cre^{-/-} and Cre^{+/-} macrophages transfected with scrambled RNA or *Mcu* siRNA (n = 3 biological replicates).



Figure 6. Defects in Intracellular Membrane Transport to the Cell Surface and in AC Corpse Degradation Contribute to Defective Efferocytosis in Drp1-Deficient Macrophages

(A) FM1-84-labeled Cre-/- and Cre+/- macrophages were transfected with scrambled RNA or Mcu siRNA and then incubated with CypHer5Elabeled ACs. Confocal microscopy was used to capture time-lapse images, with measurements beginning when the macrophages became CypHer5E-positive (t = 0). FM1-84 fluorescence was measured every 1.5 min. An example of a macrophage that had not taken up an AC is shown in the upper left set of images (black line in the graph). Bar, 5 µm. Values in the graph reflect fold change in FM1-84 fluorescence compared with t = 0. Values are mean \pm SEM, *p < 0.05 for Cre^+/siMcu and $Cre^{-/-}$ Scr versus both t = 0 and the other two groups; $^{\#}p < 0.05$ for Cre^{-/-} Scr versus t = 0 (two-way ANOVA; $n \ge 10$ cells counted per group in biological duplicates).

(B) WT macrophages were treated with 1 μ M bafilomycin (Baf) or vehicle control (Veh) and then incubated for 1 hr with PKH67-labeled AC. The percentage of macrophages with non-fragmented ACs was quantified as in Figure 4A (n = 3 biological replicates, using the average of technical duplicates for each).

(C) Macrophages similar to those in (B) were assayed for sealing around a second-encountered AC as in Figure 3C (n = 3 technical replicates).

(D) WT macrophages were treated with bafilomycin as above, 5 μ M cytochalasin D, or vehicle control and then assayed for the uptake of PKH26labeled ACs at the indicated time points (n = 3 technical replicates).

(E) A two-stage efferocytosis assay was conducted as in Figure 2C using either PKH67-labeled ACs or $6-\mu m$ phosphatidylserine (PS)-coated beads in the first round and ACs or beads in the second rounds, as indicated (n = 4 biological replicates). Bead uptake was assessed by phase microscopy.

For all panels, values are mean \pm SEM; *p < 0.05.

points but not at the earliest time point, indicative of a defect in high-burden efferocytosis (Figure 6D, dashed and dotted lines). For comparison, we treated another set of macrophages with the

inhibiting AC corpse degradation in Cre^{-/-} macrophages using the lysosomal vacuolar ATPase inhibitor bafilomycin (Yoshimori et al., 1991) could mimic the efferocytosis defects seen in Cre^{+/-} macrophages. As designed, bafilomycin-treated macrophages had a defect in AC corpse degradation (Figure 6B) without affecting mitochondrial length (Figure S5E). Next, using the two-step sealing experiment described previously, we found that bafilomycin-treated WT macrophages showed a defect in phagosome sealing around second ACs (Figure 6C) but not around first ACs (Figure S5F). Moreover, bafilomycin led to a decrease in efferocytosis at relatively late AC-incubation time actin inhibitor cytochalasin D, which is a general inhibitor of phagocytosis. In contrast to the situation with bafilomycin, cytochalasin D-treated macrophages had decreased efferocytosis at all time points (Figure 6D, solid line). Thus, inhibiting lysosomal degradation is sufficient for causing defects in phagosome sealing around a second-encountered AC and high-burden efferocytosis.

The hypothesis further predicts that WT macrophages would show a defect in high-burden efferocytosis if they were first exposed to phagocytic cargo that cannot be degraded. For this purpose, we used the two-stage uptake assay to compare



Figure 7. Mice with Myeloid Drp1 Deficiency or Drp1 Inhibition Show Impaired Efferocytosis In Vivo

(A-C) The thymuses from the two cohorts were weighed (A) and assayed for total cells (B) and TUNEL⁺ cells (C) by flow cytometry (for A and B, n = 4 mice for the PBS groups and 8 mice for the Dex groups; for C, n = 4 mice for all groups).

(D) Thymus sections were stained with TUNEL and F4/80 and then quantified for the ratio of free ACs:macrophage-associated ACs (n = 4 per group). Representative images are shown, with some of the free TUNEL⁺ cells indicated by arrowheads; arrows in upper image depict TUNEL⁺ cells associated with macrophages. Bar, 10 μm.

(legend continued on next page)

Cell

the typical protocol, in which ACs are used in both stages (AC \rightarrow AC), with that in which non-degradable 10-µm phosphatidylserine (PS)-coated latex beads were used in the first stage (bead \rightarrow AC). We also included an AC \rightarrow bead sequence, predicting that degradation of the first-encountered AC would enable secondary bead uptake. Compared with WT macrophages subjected to the AC \rightarrow AC or AC \rightarrow bead protocols, those subjected to the bead \rightarrow AC protocol showed decreased uptake of the second phagocytic substrate (Figure 6E). These combined data indicate that the AC corpse degradation defect in Drp1-deficient macrophages plays an important role in impaired uptake of a second AC.

Based on the combined *in vitro* data, we propose the following model in macrophages exposed to ACs (Figure S5G): Drp1mediated mitochondrial fission, by preventing excessive MCUmediated calcium sequestration, enables AC-induced increase in cytosolic calcium. This increase in calcium promotes initial phagosome sealing and ROS generation, leading to LAP-mediated phagolysosomal AC degradation. Corpse degradation and calcium-mediated vesicular trafficking then enables efficient delivery of membranes to phagosomes developing around a subsequently encountered AC, enabling efficient high-burden efferocytosis.

Mice with Defective Mitochondrial Fission in Myeloid Cells Show Impaired Efferocytosis *In Vivo*

To explore the role of mitochondrial fission in efferocytosis in vivo, we first investigated efferocytosis in the thymuses of $Cre^{-/-}$ and $Cre^{+/-}$ mice treated with dexamethasone, which induces thymocyte apoptosis (Park et al., 2011). As predicted, thymus size, weight, and cellularity were decreased in control Cre^{-/-} mice after dexamethasone treatment owing to the coupled processes of thymocyte apoptosis and phagocytic clearance of dead cells (Park et al., 2011), but this was not observed in the thymuses of Cre+/- mice (Figures S6A, 7A, and 7B). Consistent with these data, there was an increase in the number of TUNEL-positive (dead) cells in Cre^{+/-} thymuses (Figure 7C). To assess efferocytosis, thymus sections were assayed by immunofluorescence microscopy for TUNEL⁺ cells (ACs) that were either associated with F4/80⁺ macrophages as a result of efferocytosis or "free" of macrophages (Thorp et al., 2008). The data show that the free:associated AC ratio was higher in the Cre^{+/-} thymuses (Figure 7D), indicative of defective efferocytosis in this cohort. Note that Cre-/- and Cre^{+/-} thymocytes were equally susceptible to dexamethasone-induced apoptosis in vitro (Figure S6B). In the context that efferocytosis suppresses inflammation (Vandivier et al., 2006; Arandjelovic and Ravichandran, 2015; Rothlin et al., 2007), we found that the mRNAs encoding tumor necrosis factor alpha (TNF- α), IFN- γ , and IL-1 β as well as macrophage content were higher in the thymuses of $Cre^{+/-}$ mice (Figures S6C and S6D).

We next determined whether macrophage MCU deficiency could correct the efferocytosis defect in Drp1-inhibited mice. Mice transplanted with bone marrow from $Mcu^{-/-}$ mice or WT mice (Figure S6E) were treated with either PBS or MDIVI-1 and then challenged with dexamethasone. As designed, MDIVI-1 treatment increased mitochondrial length in thymic macrophages (Figure S6F), and this was accompanied by thymus weight loss, increases in thymus cellularity and TUNEL⁺ cells, and defective thymus efferocytosis (Figures 7F-7I, WT donor data). Note that treatment of thymocytes in vitro with MDIVI-1 did not affect apoptosis either under basal conditions or in the presence of dexamethasone (Figure S6G). Most importantly, these thymus changes in MDIVI-1-treated mice were prevented by deletion of myeloid MCU (Figures 7F–7I, *Mcu^{-/-}* donor data). Thus, disruption of the physiologic mitochondrial fission response impairs efferocytosis in vivo, and the $Mcu^{-\prime-}$ data suggest that the mitochondrial calcium sequestration mechanism revealed by the in vitro studies is relevant in vivo.

Atherosclerosis represents a more complex and pathophysiologically important scenario where macrophage efferocytosis is critically required to clear lesional dead cells and thereby limit the accumulation of cells that undergo post-apoptotic necrosis. As plagues progress, efferocytosis becomes defective, which promotes the formation of clinically dangerous necrotic plaques (Thorp and Tabas, 2009; Linton et al., 2016). To study the consequences of defective macrophage mitochondrial fission in this setting, Drp1^{f/fl} Lysmcre^{-/-} (Cre^{-/-}) and Drp1^{f/fl} Lysmcre^{+/-} (Cre^{+/-}) mice were crossed onto the Ldlr^{-/-} background and fed a high-fat Western-type diet (WD) for 12 weeks to induce advanced atherosclerosis. As expected, Cre+/- mice do not show a decrease in Drp1 expression in a type of non-myeloid vascular cell, aortic smooth muscle cells (Figure S7A). Body weight, fasting blood glucose, plasma cholesterol, triglyceride levels, and plasma lipoprotein profile were similar between the two groups of mice (Figures S7B-S7F). Most importantly, the lesions of the Cre^{+/-} mice showed significant increases in key features predicted by the hypothesis, namely, necrotic core size, lesional apoptotic cell content, and free AC:macrophageassociated AC ratio, i.e., defective efferocytosis (Figures 7I-7K). The increase in plaque necrosis was relatively specific: while necrotic area was >3-fold higher in the Cre^{+/-} versus Cre^{-/} cohort, overall lesion area was only \sim 20% higher, and there was no significant difference in the number of lesional macrophages between the two cohorts (Figure S7G). Moreover, while in theory the lesional findings could be attributable to increased susceptibility of Drp1-deficient macrophages to apoptosis, WT and Drp1-deficient macrophages showed similar apoptotic responses in vitro to two atherosclerosis-relevant apoptosis

⁽E–H) Irradiated wild-type (WT) CD1 mice were transplanted with bone marrow from WT or $Mcu^{-/-}$ CD1 mice. After 6 weeks, the mice were injected i.p. three times at 12-hr intervals with 20 mg/kg MDIVI-1 or vehicle control and then treated with dexamethasone. After 18 hr, the mice were sacrificed, and the thymuses were assayed for weight (E), cellularity (F), apoptotic cells (H), and efferocytosis as in (A)–(D) (n = 5 mice per group).

⁽I–K) $Drp1^{f/fl}$ Lysmcre^{+/-} (Cre^{-/-}) and $Drp1^{f/fl}$ Lysmcre^{+/-} (Cre^{+/-}) mice were crossed onto the Ldlr^{-/-} background and fed a high-fat Western-type diet (WD) for 12 weeks. Aortic root cross-sections were quantified necrotic area (I), TUNEL⁺ macrophages (J), and ratio of free ACs:macrophage-associated ACs (K) (n = 12-14 mice per group). Arrows in (K) show ACs. Bars, 100 µm for (I) and 10 µm for (K). For all panels, values are mean ± SEM, *p < 0.05.

inducers, oxidized LDL and 7-ketocholesterol (Figure S7H). These atherosclerosis data further show that Drp1-deficient myeloid cells have a defect in efferocytosis *in vivo* in a manner that has substantial pathologic consequences.

DISCUSSION

Efferocytosis is a critical process in maintaining normal tissue homeostasis, and defects in efferocytosis drive a number of widespread chronic inflammatory diseases (Vandivier et al., 2006; Arandjelovic and Ravichandran, 2015; Khanna et al., 2010; Thorp and Tabas, 2009). As shown here and elsewhere (Park et al., 2011), individual phagocytes must be able to ingest multiple ACs for proper functioning of efferocytosis in vivo. We and others have reasoned that precise regulatory mechanisms are needed during efferocytosis to avoid accumulation of undegraded ACs, to guard against excessive metabolic load, and to ensure proper recycling of membranes to the cell surface to enable repetitive cycles of phagocytosis. The data here have revealed a number of processes during efferocytosis that help shed light on these issues. First, macrophages undergo Drp1dependent mitochondrial fission when encountering ACs, and, when this response is blocked, there is a defect in the ability to phagocytose multiple ACs. Second, when mitochondrial fission is disabled, the normal AC-induced increase in cytosolic calcium is blunted, and vesicle membrane-mediated phagosome formation around secondarily encountered ACs is impaired. The calcium defect is associated with an increase in mitochondrial calcium and can be corrected by silencing MCU, suggesting that excessive mitochondrial calcium sequestration is a key culprit in fission-defective macrophages. Third, fissiondeficient myeloid cells have a reduced capacity for efferocytosis in vivo, including in the critically important setting of advanced atherosclerosis.

Links between calcium and efferocytosis have been suggested by previous studies (Cuttell et al., 2008; Williams et al., 2013), and our data show that mitochondrial fission plays an important role in this calcium response. As demonstrated previously, fissioned mitochondria have a decreased capacity to become tethered to the ER and to sequester ER-derived calcium, which enables increased calcium levels in the cytoplasm (Maltecca et al., 2012). Although the role of mitochondria in buffering cellular cytosolic calcium has been debated (Williams et al., 2013), the relevance to efferocytosis is supported here by cytosolic and mitochondrial calcium data; causation experiments using siMcu, BAPTA, and ionomycin; and the known role of cytosolic calcium in phagosome formation. Nonetheless, it is possible that other MCU/calcium-mediated mitochondrial processes are also involved, i.e., in addition to calcium sequestration. It is also possible that store-operated calcium entry (SOCE) contributes to the cytosolic calcium response in macrophages exposed to ACs (Cuttell et al., 2008; Gronski et al., 2009). Indeed, the fact that ER calcium levels return to baseline at times after AC exposure when cytosolic (Cre-/-) or mitochondrial (Cre^{+/-}) calcium levels are still elevated (Figures S4G, 5A, and 5B) may indicate a secondary SOCE response.

A question arising from our findings is how the first round of apoptotic cell uptake in macrophages increases Drp1. Drp1 expression rapidly increases after ACs are added to macrophages, and this response is not associated with an increase in *Drp1* mRNA. Furthermore, our studies using cycloheximide and actinomycin D suggest that AC-engagement may increase the translation of pre-existing *Drp1* mRNA (Park et al., 2015) and/or prevent the turnover of Drp1 protein (Zunino et al., 2009). Drp1 activity can also be regulated by phosphorylation (Chan, 2012; Ishihara et al., 2009), but our preliminary data thus far suggest that this mode of regulation does not play a major role in AC-induced mitochondrial fission.

While a number of diseases are driven by defective efferocytosis, advanced atherosclerosis is a particularly important example, as atherothrombotic cardiovascular disease is the leading cause of death in the industrialized world. There is now convincing evidence that efferocytosis is defective in clinically dangerous human plaques, and the consequences of this defect-plaque disruption and inflammation-play critical roles in plaque disruption and acute vascular thrombosis (Schrijvers et al., 2005; Thorp and Tabas, 2009; Linton et al., 2016). Impaired efferocytosis in advanced lesions almost certainly has multiple etiologies. Two plausible hypotheses that have been put forward recently, with supporting data in human plaques, include persistent expression of the "don't-eat-me" factor CD47 on lesional ACs (Kojima et al., 2016) and inflammation-induced cleavage of the macrophage efferocytosis receptor MerTK (Garbin et al., 2013; Cai et al., 2017). While future studies will be needed to determine whether the mitochondrial fission response becomes impaired in advanced lesional macrophages or in other pathologic settings driven by defective efferocytosis, the findings in this report support the larger concept that any process that specifically compromises the ability of macrophages to ingest multiple dead cells will likely result in dire pathologic consequences.

STAR * METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- CONTACT FOR REAGENT AND RESOURCE SHARING
- EXPERIMENTAL MODEL AND SUBJECT DETAILS • Cell Lines

 - O Primary Cell CulturesO Experimental Animals
- METHOD DETAILS

 - Fluorescent labeling of Jurkat cells
 - Induction of Apoptosis in Jurkat Cells
 - Mitochondrial Length Measurements
 - Cytosol and Mitochondrial Extracts from Cultured Macrophages
 - In Vitro Efferocytosis Assay
 - O Engulfment of IgG-Opsonized sRBCs and Latex Beads
 - Phagosome Sealing Assay
 - Time-lapse Imaging of CypHer5E
 - Lentivirus Cloning and Production
 - Cytosolic, Mitochondrial, and ER Calcium Measurements

- Analysis of Apoptotic Cell Fragmentation
- Vesicular Exocytosis Measurements Using the Styryl Dye FM1-84
- ATP Measurements
- ROS Measurements
- Lysosomal pH Measurements
- Immunoblotting
- o siRNA-Mediated Gene Silencing
- Quantitative RT-PCR
- Immunocytochemistry
- Tissue Collection and Lesion Analysis
- In Vivo Thymus Efferocytosis Assay
- Immunohistochemistry and Immunofluorescence Microscopy
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION

Supplemental Information includes seven figures and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2017.08.041.

AUTHOR CONTRIBUTIONS

Y.W., M.S., A.Y., F.R.M., and I.T. designed experiments, performed the research, analyzed the data, and wrote the manuscript. V.C.B.-L. and B.C. conducted key experiments related to intracellular pH measurements and Drp1-deficient mice, respectively. J.d.J.-S. and T.A.R. provided reagents and advice for the cellular calcium assays. M.N. offered crucial advice related to Drp1 and mitochondrial dynamics throughout the entire project and provided the $Drp1^{n//n}$ mice.

ACKNOWLEDGMENTS

We wish to thank Dr. Toren Finkel (NIH) for providing the *Mcu^{-/-}* mice, Drs. Mohammad Islam and Jahar Bhattacharya for assistance with the MCU experiments, George Kuriakose for technical contributions related to the atherosclerosis studies, Xiaobo Wang for assistance with isolation of aortic smooth muscle cells, the Herbert Irving Comprehensive Cancer Center Confocal Core Facility and Theresa Swayne and Laura Munteanu for assistance with confocal imaging, and the Columbia Center for Translational Immunology Core Facility for access to flow cytometry equipment (funded in part by NIH/NIDDK Center Grant 5P30DK063608 and by the Office of the NIH Director under Shared Instrumentation Grant S100D020056). This study was supported by American Heart Association Post-Doctoral training grant 11PRE7450075 (Y.W.); American Heart Association Post-Doctoral Fellowship grant 15POST25620024 (B.C.); KAKENHI grant 17K09885 from the Japanese Society for the Promotion of Science (M.N.); and NIH grants T32 HL007343-28 (A.Y.), R37 NS036942 (T.A.R.), R01 HL093324 (F.R.M.), and R01 HL075662, HL127464, and HL132412 (I.T.).

Received: November 17, 2016 Revised: June 21, 2017 Accepted: August 23, 2017 Published: September 21, 2017

REFERENCES

Aderem, A. (2002). How to eat something bigger than your head. Cell *110*, 5–8. Arandjelovic, S., and Ravichandran, K.S. (2015). Phagocytosis of apoptotic cells in homeostasis. Nat. Immunol. *16*, 907–917.

Blommaart, E.F., Luiken, J.J., Blommaart, P.J., van Woerkom, G.M., and Meijer, A.J. (1995). Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J. Biol. Chem. *270*, 2320–2326.

Cai, B., Thorp, E.B., Doran, A.C., Sansbury, B.E., Daemen, M.J., Dorweiler, B., Spite, M., Fredman, G., and Tabas, I. (2017). MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis. J. Clin. Invest. *127*, 564–568.

Cassidy-Stone, A., Chipuk, J.E., Ingerman, E., Song, C., Yoo, C., Kuwana, T., Kurth, M.J., Shaw, J.T., Hinshaw, J.E., Green, D.R., and Nunnari, J. (2008). Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev. Cell *14*, 193–204.

Chan, D.C. (2012). Fusion and fission: Interlinked processes critical for mitochondrial health. Annu. Rev. Genet. 46, 265–287.

Chen, T.W., Wardill, T.J., Sun, Y., Pulver, S.R., Renninger, S.L., Baohan, A., Schreiter, E.R., Kerr, R.A., Orger, M.B., Jayaraman, V., et al. (2013). Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature *499*, 295–300.

Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., and Förster, I. (1999). Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8, 265–277.

Cook, A.D., Braine, E.L., and Hamilton, J.A. (2003). The phenotype of inflammatory macrophages is stimulus dependent: Implications for the nature of the inflammatory response. J. Immunol. *171*, 4816–4823.

Cuttell, L., Vaughan, A., Silva, E., Escaron, C.J., Lavine, M., Van Goethem, E., Eid, J.P., Quirin, M., and Franc, N.C. (2008). Undertaker, a Drosophila Junctophilin, links Draper-mediated phagocytosis and calcium homeostasis. Cell *135*, 524–534.

Czibener, C., Sherer, N.M., Becker, S.M., Pypaert, M., Hui, E., Chapman, E.R., Mothes, W., and Andrews, N.W. (2006). Ca2+ and synaptotagmin VII-dependent delivery of lysosomal membrane to nascent phagosomes. J. Cell Biol. *174*, 997–1007.

de Brito, O.M., and Scorrano, L. (2008). Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 456, 605–610.

de Juan-Sanz, J., Holt, G.T., Schreiter, E.R., de Juan, F., Kim, D.S., and Ryan, T.A. (2017). Axonal endoplasmic reticulum Ca(2+) content controls release probability in CNS nerve terminals. Neuron *93*, 867–881.

Dikalov, S.I., Li, W., Doughan, A.K., Blanco, R.R., and Zafari, A.M. (2012). Mitochondrial reactive oxygen species and calcium uptake regulate activation of phagocytic NADPH oxidase. Am. J. Physiol. Regul. Integr. Comp. Physiol. *302*, R1134–R1142.

Drago, I., De Stefani, D., Rizzuto, R., and Pozzan, T. (2012). Mitochondrial Ca2+ uptake contributes to buffering cytoplasmic Ca2+ peaks in cardiomyocytes. Proc. Natl. Acad. Sci. USA *109*, 12986–12991.

Garbin, U., Baggio, E., Stranieri, C., Pasini, A., Manfro, S., Mozzini, C., Vallerio, P., Lipari, G., Merigo, F., Guidi, G., et al. (2013). Expansion of necrotic core and shedding of Mertk receptor in human carotid plaques: A role for oxidized polyunsaturated fatty acids? Cardiovasc. Res. *97*, 125–133.

Gronski, M.A., Kinchen, J.M., Juncadella, I.J., Franc, N.C., and Ravichandran, K.S. (2009). An essential role for calcium flux in phagocytes for apoptotic cell engulfment and the anti-inflammatory response. Cell Death Differ. *16*, 1323–1331.

Guo, J., Shi, T., Cui, X., Rong, Y., Zhou, T., Zhang, Z., Liu, Y., Shen, Y., and Chen, W. (2016). Effects of silica exposure on the cardiac and renal inflammatory and fibrotic response and the antagonistic role of interleukin-1 beta in C57BL/6 mice. Arch. Toxicol. *90*, 247–258.

Han, C.Z., and Ravichandran, K.S. (2011). Metabolic connections during apoptotic cell engulfment. Cell *147*, 1442–1445.

Hochreiter-Hufford, A., and Ravichandran, K.S. (2013). Clearing the dead: Apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb. Perspect. Biol. *5*, a008748.

Ishihara, N., Nomura, M., Jofuku, A., Kato, H., Suzuki, S.O., Masuda, K., Otera, H., Nakanishi, Y., Nonaka, I., Goto, Y., et al. (2009). Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nat. Cell Biol. *11*, 958–966.

Khanna, S., Biswas, S., Shang, Y., Collard, E., Azad, A., Kauh, C., Bhasker, V., Gordillo, G.M., Sen, C.K., and Roy, S. (2010). Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS ONE *5*, e9539.

Kojima, Y., Volkmer, J.P., McKenna, K., Civelek, M., Lusis, A.J., Miller, C.L., Direnzo, D., Nanda, V., Ye, J., Connolly, A.J., et al. (2016). CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature *536*, 86–90.

Kubota, Y., Takahashi, S., and Matsuoka, O. (1983). Dependence on particle size in the phagocytosis of latex particles by rabbit alveolar macrophages cultured *in vitro*. J. Toxicol. Sci. *8*, 189–195.

Linton, M.F., Babaev, V.R., Huang, J., Linton, E.F., Tao, H., and Yancey, P.G. (2016). Macrophage apoptosis and efferocytosis in the pathogenesis of atherosclerosis. Circ. J. *80*, 2259–2268.

Lu, N., and Zhou, Z. (2012). Membrane trafficking and phagosome maturation during the clearance of apoptotic cells. Int. Rev. Cell Mol. Biol. 293, 269–309.

Luchsinger, L.L., de Almeida, M.J., Corrigan, D.J., Mumau, M., and Snoeck, H.W. (2016). Mitofusin 2 maintains haematopoietic stem cells with extensive lymphoid potential. Nature *529*, 528–531.

Majumdar, A., Cruz, D., Asamoah, N., Buxbaum, A., Sohar, I., Lobel, P., and Maxfield, F.R. (2007). Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol. Biol. Cell *18*, 1490–1496.

Maltecca, F., De Stefani, D., Cassina, L., Consolato, F., Wasilewski, M., Scorrano, L., Rizzuto, R., and Casari, G. (2012). Respiratory dysfunction by AFG3L2 deficiency causes decreased mitochondrial calcium uptake via organellar network fragmentation. Hum. Mol. Genet. *21*, 3858–3870.

Martinez, J., Almendinger, J., Oberst, A., Ness, R., Dillon, C.P., Fitzgerald, P., Hengartner, M.O., and Green, D.R. (2011). Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the efficient clearance of dead cells. Proc. Natl. Acad. Sci. USA *108*, 17396–17401.

Martinez, J., Malireddi, R.K., Lu, Q., Cunha, L.D., Pelletier, S., Gingras, S., Orchard, R., Guan, J.L., Tan, H., Peng, J., et al. (2015). Molecular characterization of LC3-associated phagocytosis reveals distinct roles for Rubicon, NOX2 and autophagy proteins. Nat. Cell Biol. *17*, 893–906.

Martinez, J., Cunha, L.D., Park, S., Yang, M., Lu, Q., Orchard, R., Li, Q.Z., Yan, M., Janke, L., Guy, C., et al. (2016). Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. Nature *533*, 115–119.

Muller, W.A., Steinman, R.M., and Cohn, Z.A. (1983). Membrane proteins of the vacuolar system. III. Further studies on the composition and recycling of endocytic vacuole membrane in cultured macrophages. J. Cell Biol. *96*, 29–36.

Nomura, M., Liu, J., Rovira, I.I., Gonzalez-Hurtado, E., Lee, J., Wolfgang, M.J., and Finkel, T. (2016). Fatty acid oxidation in macrophage polarization. Nat. Immunol. *17*, 216–217.

Otera, H., Wang, C., Cleland, M.M., Setoguchi, K., Yokota, S., Youle, R.J., and Mihara, K. (2010). Mff is an essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in mammalian cells. J. Cell Biol. *191*, 1141–1158.

Pan, X., Liu, J., Nguyen, T., Liu, C., Sun, J., Teng, Y., Fergusson, M.M., Rovira, I.I., Allen, M., Springer, D.A., et al. (2013). The physiological role of mitochon-

drial calcium revealed by mice lacking the mitochondrial calcium uniporter. Nat. Cell Biol. *15*, 1464–1472.

Park, D., Han, C.Z., Elliott, M.R., Kinchen, J.M., Trampont, P.C., Das, S., Collins, S., Lysiak, J.J., Hoehn, K.L., and Ravichandran, K.S. (2011). Continued clearance of apoptotic cells critically depends on the phagocyte Ucp2 protein. Nature *477*, 220–224.

Park, S.J., Lee, H., Jo, D.S., Jo, Y.K., Shin, J.H., Kim, H.B., Seo, H.M., Rubinsztein, D.C., Koh, J.Y., Lee, E.K., and Cho, D.H. (2015). Heterogeneous nuclear ribonucleoprotein A1 post-transcriptionally regulates Drp1 expression in neuroblastoma cells. Biochim. Biophys. Acta *1849*, 1423–1431.

Rothlin, C.V., Ghosh, S., Zuniga, E.I., Oldstone, M.B., and Lemke, G. (2007). TAM receptors are pleiotropic inhibitors of the innate immune response. Cell *131*, 1124–1136.

Ryan, T.A., Smith, S.J., and Reuter, H. (1996). The timing of synaptic vesicle endocytosis. Proc. Natl. Acad. Sci. USA 93, 5567–5571.

Schindelin, J.I., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietszch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fijl: an open-source platform for biological-image analysis. Nat. Methods *9*, 676–682.

Schrijvers, D.M., De Meyer, G.R., Kockx, M.M., Herman, A.G., and Martinet, W. (2005). Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, 1256–1261.

Thorp, E., and Tabas, I. (2009). Mechanisms and consequences of efferocytosis in advanced atherosclerosis. J. Leukoc. Biol. *86*, 1089–1095.

Thorp, E., Cui, D., Schrijvers, D.M., Kuriakose, G., and Tabas, I. (2008). Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of *apoe-/-*mice. Arterioscler. Thromb. Vasc. Biol. 28, 1421–1428.

Vandivier, R.W., Henson, P.M., and Douglas, I.S. (2006). Burying the dead: The impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest *129*, 1673–1682.

Williams, G.S., Boyman, L., Chikando, A.C., Khairallah, R.J., and Lederer, W.J. (2013). Mitochondrial calcium uptake. Proc. Natl. Acad. Sci. USA *110*, 10479–10486.

Wu, J., Liu, L., Matsuda, T., Zhao, Y., Rebane, A., Drobizhev, M., Chang, Y.F., Araki, S., Arai, Y., March, K., et al. (2013). Improved orange and red $Ca^2 \pm$ indicators and photophysical considerations for optogenetic applications. ACS Chem. Neurosci. *4*, 963–972.

Yoshimori, T., Yamamoto, A., Moriyama, Y., Futai, M., and Tashiro, Y. (1991). Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J. Biol. Chem. *266*, 17707–17712.

Zunino, R., Braschi, E., Xu, L., and McBride, H.M. (2009). Translocation of SenP5 from the nucleoli to the mitochondria modulates DRP1-dependent fission during mitosis. J. Biol. Chem. *284*, 17783–17795.

STAR*METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Mouse anti-Drp1 (Clone 8/DLP1)	BD Biosciences	Cat# 611113; RRID:AB_398424
Rabbit anti-Drp1	Cell Signaling Technology	Cat# 8570S; RRID:AB_10950498
Mouse anti-VDAC1	Abcam	Cat# ab14734; RRID:AB_443084
Mouse anti-ATP5α	Abcam	Cat# ab110273; RRID:AB_10858175
Rabbit anti-GAPDH	Cell Signaling Technology	Cat# 5174S; RRID:AB_10622025
Mouse anti-PDH1α	Abcam	Cat# ab110330; RRID:AB_10858459
Goat anti-Mff	Santa Cruz Biotechnology	Cat# SC-168593; RRID:AB_10839060
Rabbit anti-Mcu1	Sigma Life Sciences	Cat# PA016480
Mouse anti-β-actin	Santa Cruz Biotechnology	Cat# SC-47778; RRID:AB_626632
Rat anti-F4/80 (Clone BM8)	eBiosciences	Cat# 14-4801-82; RRID:AB_467558
Rat anti-Mac3 (M3/84)	BD Biosciences	Cat# 553322; RRID:AB_394780
Rabbit anti-COX IV	Cell Signaling Technology	Cat# 4844S
Rabbit anti-LC3	MBL Intern. Corporation	Cat# PM036; RRID:AB_2274121
Goat anti-mouse (HRP)	Invitrogen	Cat# 32230
Goat anti-rabbit (HRP)	Invitrogen	Cat# 32260
Rabbit anti-goat (HRP)	Invitrogen	Cat# 81-1620
Goat anti-mouse (AF488)	Invitrogen	Cat# A11001
Goat anti-rat (AF488)	Invitrogen	Cat# A11006; RRID:AB_141373
Goat anti-rabbit (AF488)	Invitrogen	Cat# A11034
Goat anti-rabbit (AF555)	Invitrogen	Cat# A21428; RRID:AB_141784
Rat anti-CD16/CD32	BD Biosciences	Cat# 553142; RRID:AB_394657
Rat anti-F4/80 (FITC)	Biolegend	Cat# 123107; RRID:AB_893500
Rat anti-CD68 (APC)	Biolegend	Cat# 137007; RRID:AB_10575299
Rat ant-FCγRI (PE)	Biolegend	Cat# 139303; RRID:AB_10613467
Anti-sRBC	Rockland	Cat # 213-4139; RRID:AB_220373
Bacterial and Virus Strains		
VSV-G Pseudotyped Lentivirus	ALSTEM	http://www.alstembio.com/
Chemicals, Peptides, and Recombinant Proteins		
Dulbecco's Modified Eagle Media (DMEM)	Corning	Cat# 10-013-CV
Roswell Park Memorial Institute (RPMI) 1640 Media	Corning	Cat# 10-040-CV
DMEM/Nutrient Mixture F-12 (DMEM/F12)	GIBCO	Cat# 11320-033
Opti-MEM	GIBCO	Cat# 31985-070
1X HBSS	Corning	Cat# 21-022-CV
1X PBS	Corning	Cat# 21-040-CV
CellStripper	Corning	Cat# 25-056-CI
Heat-Inactivated Fetal Bovine Serum	GIBCO	Cat# 10438-026
Penicillin/Streptomycin	Corning	Cat# 30-002-CI
Human Granulocyte Colony Stimulating Factor (GM-CSF)	PeproTech	Cat# 300-03
HISTOPAQUE-1077	Sigma-Aldrich	Cat# 10771-100ML
Collagenase I	Sigma-Aldrich	Cat# 1148089
Soybean Trypsin Inhibitor	Sigma-Aldrich	Cat# T9003
Elastase	Sigma-Aldrich	Cat# E7885

(Continued on next page)

Cell

tinued		

Continued			
REAGENT or RESOURCE	SOURCE	IDENTIFIER	
2-Well Glass Slides	Thermo Scientific	Cat# 155380	
4-Well Glass Slides	Thermo Scientific	Cat# 155383	
8-Well Glass Slides	Thermo Scientific	Cat# 155411	
Novex 4-20% Tris-Glycine Mini Gels, 15-well	Invitrogen	Cat# XP04205BOX	
4X Laemmli Buffer	Bio-Rad	Cat# 1610747	
MitoTracker Red CMXRos	Molecular Probes	Cat# M7512	
PKH67 Fluorescent Cell Linker	Sigma-Aldrich	Cat# PKH67GL-1KT	
PKH26 Fluorescent Cell Linker	Sigma-Aldrich	Cat# PKH26GL-1KT	
Cell-Vue Claret Fluorescent Cell Linker	Sigma-Aldrich	Cat# MINCLARET-1KT	
Diluent C	Sigma-Aldrich	Cat# CGLDIL	
Calcein-AM	Molecular Probes	Cat# C3100MP	
MDIVI-1	Sigma-Aldrich	Cat# M0199	
Cytochalasin D	Sigma-Aldrich	Cat# C8273	
EZ-Link Sulfo-NHS Ester	Thermo Scientific	Cat# 21217	
Streptavidin (AF568)	Invitrogen	Cat# S11226	
CypHer5E Mono NHS Ester	GE Healthcare	Cat# PA15401	
Hoechst 33342	Thermo Scientific	Cat# 62249	
Digitonin	Sigma-Aldrich	Cat# D141	
H2-DCFDA	Invitrogen	Cat# D399	
Tert-Butyl Hydroperoxide	Alfa-Aesar	Cat# A13926	
FM1-84	Biotium	Cat# 70046	
Bafilomycin A1	Sigma-Aldrich	Cat# B1793	
Biotinylated-Phosphatidylserine	Echelon Biosciences	Cat# L-31B16	
Streptavidin-Coated Polystyrene Beads	Spherotech	Cat# SVP-60-5	
Dexamethasone	Calbiochem	Cat# 265005	
Actinomycin D	Sigma-Aldrich	Cat# A1410	
Cycloheximide	Sigma-Aldrich	Cat# 7698	
10 µm-coated microspheres	Bangs Laboratories	Cat# CP10N	
4 μm-coated microspheres	Bangs Laboratories	Cat# PC05N	
Sheep RBCs	Rockland	Cat# R405-0050	
Rapamycin	Sigma-Aldrich	Cat# R0395	
4 μm-coated microspheres	Thermo-Fisher	Cat# F8859	
Annexin V (FITC)	BD Biosciences	Cat# 560931	
Oxidized LDL	Alfa Aesar	Cat# J65591	
7-Ketocholesterol	Sigma-Aldrich	Cat# C2394	
Zymosan A	Sigma-Aldrich	Cat# Z4250	
Lipofectamine 2000	Life Technologies	Cat# 11668-030	
Lipofectamine RNAiMax	Life Technologies	Cat# 13778-150	
Neomycin	Sigma-Aldrich	Cat# N1142	
Polymyxin B	Sigma-Aldrich	Cat# P4932	
Dextran, Fluorescein, and Tetramethylrhodamine	Invitrogen	D1951	
Heparin	Sigma-Aldrich	Cat# H3393	
40 μm Nylon Cell Strainers	BD Falcon	Cat# 352340	
Power SYBR Green PCR Master Mix	Applied Biosystems	Cat# 4367659	
Critical Commercial Assays			
Qproteome Mitochondria Isolation Kit	QIAGEN	Cat# 37612	
ATP Detection Kit	Abcam	Cat# ab83355	

(Continued on next page)

Continued			
REAGENT or RESOURCE	SOURCE	IDENTIFIER	
RNeasy Micro Kit	QIAGEN	Cat# 74004	
TUNEL Kit	Roche	Cat# 12156792910	
Total Cholesterol Kit	Wako Diagnostics	Cat# 999-02601	
HDL Cholesterol Kit	Wako Diagnostics	Cat# 997-01301	
Triglycerides Kit Color A	Wako Diagnostics	Cat# 994-02891	
Triglycerides Kit Color B	Wako Diagnostics	Cat# 990-02991	
Experimental Models: Cell Lines			
Human: Jurkat cells	ATCC	ATCC TIB-152	
Mouse: L-929 Fibroblast cells	ATCC	ATCC CCL-1	
Mouse: Bone Marrow-Derived Macrophage cells	This paper	N/A	
Mouse: Elicited Peritoneal Macrophage cells	This paper	N/A	
Mouse: Vascular Smooth Muscle cells	This paper	N/A	
Human: Peripheral Blood Monocyte-Derived Macrophage cells	This paper	N/A	
Experimental Models: Organisms/Strains			
Mouse: C57BL/6J	The Jackson Laboratory	JAX: 000664	
Mouse: LdIr ^{-/-} C57BL/6J	The Jackson Laboratory	JAX: 002207	
Mouse: Drp1 ^{fl/fl} C57BL/6J	Ishihara et al., 2009	N/A	
Mouse: Lysmcre C57BL/6J	Clausen et al., 1999	N/A	
Mouse: CD-1	Charles River	Crl: 022	
Mouse: Mcu ^{-/-} CD-1	Pan et al., 2013	N/A	
Oliaonucleotides			
ON-TARGET plus non-targeting pool	GE Healthcare Dharmacon	D-001810-10-05	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool	GE Healthcare Dharmacon GE Healthcare Dharmacon	D-001810-10-05 L-012092-00	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon	D-001810-10-05 L-012092-00 E-041534-00	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1 Mouse: Mfn1	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1 Mouse: Mfn1 Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1 Mouse: Mfn1 Mouse: <i>Drp1</i> Forward ATAAGCTGCAGGACGTCTTC Mouse: <i>Drp1</i> Reverse TGACCACACCAGTTCCTCT	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1 Mouse: Mfn1 Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Reverse TGACCACACCAGTTCCTCT Mouse: β-Actin Forward GGCTGTATTCCCCTCCATCG	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1 Mouse: Mfn1 Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Reverse TGACCACACCAGTTCCTCT Mouse: β-Actin Forward GGCTGTATTCCCCTCCATCG Mouse: β-Actin Reverse CCAGTTGGTAACAATGCCATGT	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank PrimerBank	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1 Mouse: Mfn1 Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Reverse TGACCACACCAGTTCCTCT Mouse: β-Actin Forward GGCTGTATTCCCCTCCATCG Mouse: β-Actin Reverse CCAGTTGGTAACAATGCCATGT Mouse: TNFα Forward CCCTCACACTCAGATCATCTTCT	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank PrimerBank Guo et al., 2016	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1 Mouse: Mfn1 Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Reverse TGACCACACCAGTTCCTCT Mouse: β -Actin Forward GGCTGTATTCCCCTCCATCG Mouse: β -Actin Reverse CCAGTTGGTAACAATGCCATGT Mouse: $TNF\alpha$ Forward CCCTCACACTCAGATCATCTTCT Mouse: $TNF\alpha$ Reverse GCTACGACGTGGGCTACAG	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1 Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Reverse TGACCACACCAGTTCCTCT Mouse: β -Actin Forward GGCTGTATTCCCCTCCATCG Mouse: β -Actin Reverse CCAGTTGGTAACAATGCCATGT Mouse: $TNF\alpha$ Forward CCCTCACACTCAGATCATCTTCT Mouse: $TNF\alpha$ Reverse GCTACGACGTGGGCTACAG Mouse: $IL1\beta$ Forward GCAACTGTTCCTGAACTCAACT	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A N/A	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1 Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Reverse TGACCACACCAGTTCCTCT Mouse: β -Actin Forward GGCTGTATTCCCCTCCATCG Mouse: β -Actin Reverse CCAGTTGGTAACAATGCCATGT Mouse: $TNF\alpha$ Forward CCCTCACACTCAGATCATCTTCT Mouse: $TNF\alpha$ Reverse GCTACGACGTGGGCTACAG Mouse: $IL1\beta$ Forward GCAACTGTTCCTGAACTCAACT Mouse: $IL1\beta$ Reverse ATCTTTTGGGGTCCGTCAACT	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016 Guo et al., 2016	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A N/A N/A	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1 Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Reverse TGACCACACCAGTTCCTC Mouse: β -Actin Forward GGCTGTATTCCCCTCCATCG Mouse: β -Actin Reverse CCAGTTGGTAACAATGCCATGT Mouse: $TNF\alpha$ Forward CCCTCACACTCAGATCATCTTCT Mouse: $TNF\alpha$ Forward CCCTCACACTCAGATCATCTTCT Mouse: $TNF\alpha$ Reverse GCTACGACGTGGGCTACAG Mouse: $IL1\beta$ Forward GCAACTGTTCCTGAACTCAACT Mouse: $IL1\beta$ Reverse ATCTTTTGGGGTCCGTCAACT Mouse: $IFN\gamma$ Forward ATGAACGCTACACACTGCATC	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 PrimerBank	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A N/A N/A N/A https://pga.mgh.harvard.edu/primerbank/	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1 Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Reverse TGACCACACCAGTTCCTCT Mouse: β -Actin Forward GGCTGTATTCCCCTCCATCG Mouse: β -Actin Reverse CCAGTTGGTAACAATGCCATGT Mouse: $TNF\alpha$ Forward CCCTCACACTCAGATCATCTTCT Mouse: $TNF\alpha$ Reverse GCTACGACGTGGGCTACAG Mouse: $IL1\beta$ Forward GCAACTGTTCCTGAACTCAACT Mouse: $IL1\beta$ Reverse ATCTTTTGGGGTCCGTCAACT Mouse: $ILN\gamma$ Forward ATGAACGCTACACACTGCATC Mouse: $IFN\gamma$ Reverse CCATCCTTTTGCCAGTTCCTC	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 PrimerBank PrimerBank	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A N/A N/A N/A https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1 Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Reverse TGACCACACCAGTTCCTCT Mouse: β -Actin Forward GGCTGTATTCCCCTCCATCG Mouse: β -Actin Reverse CCAGTTGGTAACAATGCCATGT Mouse: $TNF\alpha$ Forward CCCTCACACTCAGATCATCTTCT Mouse: $TNF\alpha$ Reverse GCTACGACGTGGGCTACAG Mouse: $IL1\beta$ Forward GCAACTGTTCCTGAACTCAACT Mouse: $IL1\beta$ Reverse ATCTTTTGGGGTCCGTCAACT Mouse: $IFN\gamma$ Forward ATGAACGCTACACACTGCATC Mouse: $IFN\gamma$ Reverse CCATCCTTTTGCCAGTTCCTC Mouse: $IFN\gamma$ Reverse CCATCCTTTTGCCAGTTCCTC Mouse: $IL6$ Forward CCAAGAGGTGAGTGCTTCCC	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 PrimerBank PrimerBank PrimerBank	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A N/A N/A N/A https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1 Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Reverse TGACCACACCAGTTCCTCT Mouse: β -Actin Forward GGCTGTATTCCCCTCCATCG Mouse: β -Actin Reverse CCAGTTGGTAACAATGCCATGT Mouse: $TNF\alpha$ Reverse GCTACGACGTGGGCTACAG Mouse: $TNF\alpha$ Reverse GCTACGACGTGGGCTACAG Mouse: $TNF\alpha$ Reverse GCTACGACGTGGGCTACAG Mouse: $IL1\beta$ Forward GCAACTGTTCCTGAACTCAACT Mouse: $IL1\beta$ Reverse ATCTTTTGGGGTCCGTCAACT Mouse: $IFN\gamma$ Forward ATGAACGCTACACACTGCATC Mouse: $IFN\gamma$ Reverse CCATCCTTTTGCCAGTTCCTC Mouse: $IL6$ Forward CCAAGAGGTGAGTGCTTCCC Mouse: $IL6$ Reverse CTGTTGTTCAGACTCTCTCCCT	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 PrimerBank PrimerBank PrimerBank PrimerBank PrimerBank	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A N/A N/A N/A https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/	
ON-TARGET plus non-targeting poolHuman: DNML1 SMARTpoolMouse: Mff SMARTpoolMouse: DNML1Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTCMouse: Drp1 Forward ATAAGCTGCAGGACGTCTTCMouse: Drp1 Reverse TGACCACACCAGTTCCTCTMouse: β -Actin Forward GGCTGTATTCCCCTCCATCGMouse: β -Actin Reverse CCAGTTGGTAACAATGCCATGTMouse: $TNF\alpha$ Forward CCCTCACACTCAGATCATCTTCTMouse: $TNF\alpha$ Reverse GCTACGACGTGGGCTACAGMouse: $TL1\beta$ Forward GCAACTGTTCCTGAACTCAACTMouse: $IL1\beta$ Reverse ATCTTTTGGGGTCCGTCAACTMouse: $IFN\gamma$ Forward ATGAACGCTACACACTGCATCMouse: $IFN\gamma$ Reverse CCATCCTTTTGCCAGTTCCTCMouse: $IL6$ Forward CCAAGAGGTGAGTGCTTCCCMouse: $IL6$ Reverse CTGTTGTTCAGACTCTCCCTMouse: $IL6$ Reverse CTGTTGTTCAGACTCTCCCTMouse: $Nos2$ Forward GTTCTCAGCCCAACAATACAAGA	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 PrimerBank PrimerBank PrimerBank PrimerBank Guo et al., 2016	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A N/A N/A https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A	
ON-TARGET plus non-targeting pool Human: DNML1 SMARTpool Mouse: Mff SMARTpool Mouse: DNML1 Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTC Mouse: Drp1 Reverse TGACCACACCAGTTCCTCT Mouse: β -Actin Forward GGCTGTATTCCCCTCCATCG Mouse: β -Actin Reverse CCAGTTGGTAACAATGCCATGT Mouse: $TNF\alpha$ Forward CCCTCACACTCAGATCATCTTCT Mouse: $TNF\alpha$ Reverse GCTACGACGTGGGCTACAG Mouse: $IL1\beta$ Forward GCAACTGTTCCTGAACTCAACT Mouse: $IL1\beta$ Reverse ATCTTTTGGGGTCCGTCAACT Mouse: $IFN\gamma$ Forward ATGAACGCTACACACTGCATC Mouse: $IFN\gamma$ Reverse CCATCCTTTTGCCAGTTCCCC Mouse: $IL6$ Forward CCAAGAGGTGAGTGCTTCCC Mouse: $IL6$ Reverse CTGTTGTTCAGACTCTCTCCCT Mouse: $Nos2$ Forward GTTCTCAGCCCAACAATACAAGA Mouse: $Nos2$ Reverse GTGGACGGGTCGATGTCAC	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 PrimerBank PrimerBank PrimerBank PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 Guo et al., 2016	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A N/A N/A https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A	
ON-TARGET plus non-targeting poolHuman: DNML1 SMARTpoolMouse: Mff SMARTpoolMouse: DNML1Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTCMouse: Drp1 Forward ATAAGCTGCAGGACGTCTTCMouse: Drp1 Reverse TGACCACACCAGTTCCTCTMouse: β -Actin Forward GGCTGTATTCCCCTCCATCGMouse: β -Actin Reverse CCAGTTGGTAACAATGCCATGTMouse: $TNF\alpha$ Forward CCCTCACACTCAGATCATCTTCTMouse: $TNF\alpha$ Reverse GCTACGACGTGGGCTACAGMouse: $IL1\beta$ Forward GCAACTGTTCCTGAACTCAACTMouse: $IFN\gamma$ Forward ATGAACGCTACACACTGCATCMouse: $IFN\gamma$ Reverse CCATCCTTTTGCCAGTTCCTCMouse: $IL6$ Forward CCAAGAGGTGAGTGCTTCCCMouse: $IL6$ Reverse CTGTTGTTCAGACTCTCCCTMouse: $Nos2$ Forward GTTCTCAGCCCAACATACAAGAMouse: $Nos2$ Reverse GTGGACGGGTCGATGTCACMouse: $Nos2$ Reverse GTGGACGCAAGCCTTAGAG	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 PrimerBank PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 Guo et al., 2016	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A N/A https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A	
ON-TARGET plus non-targeting poolHuman: DNML1 SMARTpoolMouse: Mff SMARTpoolMouse: DNML1Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTCMouse: Drp1 Forward ATAAGCTGCAGGACGTCTTCMouse: Drp1 Reverse TGACCACACCAGTTCCTCTMouse: β -Actin Forward GGCTGTATTCCCCTCCATCGMouse: β -Actin Reverse CCAGTTGGTAACAATGCCATGTMouse: TNF α Forward CCCTCACACTCAGATCATCTTCTMouse: TNF α Reverse GCTACGACGTGGGCTACAGMouse: IL1 β Forward GCAACTGTTCCTGAACTCAACTMouse: IL1 β Reverse ATCTTTTGGGGTCCGTCAACTMouse: IFN γ Forward ATGAACGCTACACACTGCATCMouse: IFN γ Reverse CCATCCTTTGCCAGTTCCCCMouse: IL6 Forward CCAAGAGGTGAGTGCTTCCCMouse: IL6 Forward CCAAGAGGTGAGTGCTTCCCMouse: Nos2 Forward GTTCTCAGCCCAACAATACAAGAMouse: Nos2 Reverse GTGGACGGGTCGATGTCACMouse: Nos2 Reverse GTGGACGGGTCGATGTCACMouse: Arg1 Forward CTCCAAGCCAAAGTCCTTAGAGMouse: Arg1 Reverse AGGAGCTGTCATTAGGGACA	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A N/A https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A N/A N/A	
ON-TARGET plus non-targeting poolHuman: DNML1 SMARTpoolMouse: Mff SMARTpoolMouse: DNML1Mouse: Drp1 Forward ATAAGCTGCAGGACGTCTTCMouse: Drp1 Forward ATAAGCTGCAGGACGTCTTCMouse: Drp1 Reverse TGACCACACCAGTTCCTCTMouse: β -Actin Forward GGCTGTATTCCCCTCCATCGMouse: β -Actin Reverse CCAGTTGGTAACAATGCCATGTMouse: TNF α Forward CCCTCACACTCAGATCATCTTCTMouse: TNF α Reverse GCTACGACGTGGGCTACAGMouse: IL1 β Forward GCAACTGTTCCTGAACTCAACTMouse: IL1 β Reverse ATCTTTTGGGGTCCGTCAACTMouse: IFN γ Forward ATGAACGCTACACACTGCATCMouse: IL6 Forward CCAAGAGGTGAGTGCTTCCCMouse: IL6 Forward CCAAGAGGTGAGTGCTTCCCMouse: Nos2 Forward GTTCTCAGCCCAACATACAAGAMouse: Nos2 Reverse GTGGACGGGTCGATGTCACMouse: Nos2 Reverse GTGGACGGGTCGATGTCACMouse: Arg1 Forward CTCCAAGCCAAAGTCCTTAGGGACAMouse: Arg1 Forward CTCTGTTCAGCTATTGGACACAMouse: Arg1 Forward CTCTGTTCAGCTATTGGACACAMouse: Mrc1 Forward CTCTGTTCAGCTATTGGACAMouse: Mrc1 Forward CTCTGTTCAGCTATTGGACGC	GE Healthcare Dharmacon GE Healthcare Dharmacon GE Healthcare Dharmacon QIAGEN QIAGEN PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 Guo et al., 2016 PrimerBank PrimerBank PrimerBank PrimerBank Guo et al., 2016 Guo et al., 2016	D-001810-10-05 L-012092-00 E-041534-00 SI0098226 and SI00982240 SI01304408 and SI01304401 https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A N/A N/A https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ https://pga.mgh.harvard.edu/primerbank/ N/A N/A N/A N/A N/A N/A N/A N/	

(Continued on next page)

-		
	-	
<u> </u>	<u> </u>	

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
Mouse: Retnla Forward CCAATCCAGCTAACTATCCCTCC	Nomura et al., 2016	N/A
Mouse: Retnla Reverse ACCCAGTAGCAGTCATCCCA	Nomura et al., 2016	N/A
Recombinant DNA		
CK-GCaMP6f	Chen et al., 2013	Addgene: Plasmid# 40755
Mito-CAR-GECO1	Wu et al., 2013	Addgene: Plasmid# 46022
ER-GCaMP-150	de Juan-Sanz et al., 2017	Addgene: Plasmid# 86918
Software and Algorithms		
DP Manager Basic Imaging Software	Olympus	Version 3.1
NIS-Elements	Nikon	Advanced Research
Leica Application Suite	Leica	Advanced Fluorescence
ImageJ	NIH	https://imagej.nih.gov/ij/
FIJI	Schindelin et al., 2012	www.fiji.sc
MetaMorph	Molecular Devices	Version 7.10
PRISM	GraphPad Software	Version 6
FlowJo	FlowJo	Version 10
Other		
Mouse Diet: High-Fat Western Diet	Envigo	Cat# TD.88137
Lentivirus Cloning and Packaging Services	ALSTEM	www.alstembio.com
Lenti-X qRT-PCR Titration Kit	Clontech	Cat# 631235
Genotyping Service	Genetyper	www.genetyper.com

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Ira Tabas (iat1@cumc.columbia.edu). An MTA was obtained for the transfer of $Mcu^{-/-}$ mice.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell Lines

Jurkat (human T lymphocytes), L-929 (mouse fibroblasts), and embryonic fibroblast (mouse) cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (HI-FBS), and 10 U/mL Penicillin and 100 µg/mL Streptomycin. Cells were cultured in a humidified CO₂ incubator at 37°C. The Jurkat cell line was originally established from the peripheral blood of a 14-year-old boy with T cell leukemia. L-929 cells were originally derived from normal adipose tissue of a 100-day-old male C3H/An mouse. Murine embryonic fibroblasts were established from CD-1 mouse embryos, sex undetermined.

Primary Cell Cultures

For bone marrow-derived macrophages (BMDMs), bone marrow cells from 8-12 week old mice (either male or female) were cultured for 7-9 days in DMEM supplemented with 10% (vol/vol) heat-inactivated FBS, 10 U/mL penicillin, 100 µg/mL streptomycin, and 20% (vol/vol) L-929 fibroblast conditioned media.

University Institutional Review Board and Health Insurance Portability and Accountability Act guidelines were followed for isolating peripheral human blood monocytes. For human macrophages, peripheral human blood monocytes were isolated from buffy coats of de-identified healthy adult volunteers (New York Blood Center; exact age and sex not known) and subsequently purified in a discontinuous gradient of FicoII-Hypaque. These cells were then cultured for 10 days in Roswell Park Memorial Institute 1640 media (RPMI-1640) containing 10% heat-inactivated FBS (vol/vol), 10 U/mL penicillin, 100 µg/mL streptomycin, and 10 ng/ml of recombinant human granulocyte macrophage colony-stimulating factor (GM-CSF).

For vascular smooth muscle cells, thoracic aortas were stripped of adventitia with the endothelium denuded with a scalpel. Aortas were then placed in an enzyme solution containing collagenase (1 mg/ml), soybean trypsin inhibitor (1 mg/ml), and elastase (0.744 U/ml) in 1X HBSS for one hr. Cells were triturated, centrifuged at 1.5K RPMs for 5 min, and then subsequently cultured in DMEM/F12 medium supplemented with 20% heat-inactivated FBS (vol/vol), 10 U/mL penicillin, and 100 µg/mL streptomycin. Cells were cultured in a humidified CO₂ incubator at 37°C.

Experimental Animals

Animal protocols were approved by Columbia University's institutional animal care and use committee. All animals were cared for according to the NIH guidelines for the care and use of laboratory animals. Mice were socially housed under a 12 hr light/dark cycle with ad libitum access to water and food. Mice were randomly assigned to experimental groups by investigators. Investigators were blinded for the atherosclerosis studies, but were not blinded for the dexamethasone-induced thymus injury studies. Age and sex are described below.

METHOD DETAILS

Fluorescent labeling of Jurkat cells

Calcein-AM labeling was carried out prior to induction of apoptosis. Jurkat cells were rinsed with 1X PBS, and then and incubated for 30 min at room temperature with 5 μ M Calcein-AM at a cell concentration of 1-10 × 10⁶ cells/ml. Cells were then washed twice with DMEM containing 10% heat-inactivated FBS. PKH and Cell-Vue Claret labeling was conducted after the induction of apoptosis. Apoptotic Jurkat cells were rinsed once with serum-free DMEM, resuspended at a concentration of 2 × 10⁷ cells/ml in Diluent C (see Resource Table), and incubated for 2-3 min with 4 μ L of PKH or Cell-Vue Claret. The cells were then rinsed twice with DMEM containing 10% heat-inactivated FBS.

Induction of Apoptosis in Jurkat Cells

Apoptotic cells were generated by irradiating Jurkat cells under a UV (254 nm) lamp for 15 min followed by incubation under normal cell culture conditions for 2-3 hr. This method routinely yielded greater than 80% Annexin V-positive cells.

Mitochondrial Length Measurements

To view mitochondria, macrophages were labeled with 100 nM MitoTracker Red for 5 min in serum-free DMEM. MitoTracker Redlabeled macrophages were then incubated with PKH67-labeled ACs for 45 min. Unbound ACs were removed by rinsing the monolayer, and cells were viewed by live-cell confocal fluorescence microscopy (NIKON A1 Confocal microscope, 100X oil objective). Random areas containing ACs were selected, and 0.5-µm z-steps were captured for the entire height of MitoTracker Red-labeled macrophages. The length of individual mitochondrial branches was traced using ImageJ software, and average mitochondria branch length per cell was quantified.

Cytosol and Mitochondrial Extracts from Cultured Macrophages

Using the Qproteome Mitochondria Isolation Kit, $\sim 5 \times 10^6$ macrophages were removed from wells by non-enzymatic dissociation, collected by centrifugation, and washed once with ice-cold 1X PBS. The pellets were lysed on ice with 700 µl lysis buffer, which was provided in the kit and contained protease inhibitors, and then centrifuged at 1000 x g for 5 min. The supernatant fractions (cytosol extract) were concentrated using Amicon Ultra-15 centrifugal filter units. The pellets were further processed in 700 µl ice-cold disruption buffer, which was provided in the kit and contained protease inhibitors, vortexed for 15 s, and centrifuged at 1500 x g for 10 min. This procedure was repeated one time, and the supernatant fractions were combined and centrifuged at 6000 x g for 10 min at 4°C. The lysates were mixed with Laemmli buffer and subjected to SDS-polyacrylamide gel electrophoresis (PAGE).

In Vitro Efferocytosis Assay

Peritoneal macrophages harvested four days after intraperitoneal injection of methyl-BSA in mice had been previously immunized with methyl-BSA (Cook et al., 2003) or bone marrow-derived macrophages were plated in 24-well dishes at a density of 0.2×10^6 cells per well. Fluorescent ACs were added to macrophages for 45 min unless noted otherwise, followed by vigorous washing 3 times with 1X PBS. Cells were either dissociated from the wells and analyzed by flow cytometry (BD Canto II) or fixed with 4% formaldehyde and imaged with an Olympus DP71 CCD camera attached to an Olympus IX-70 inverted epifluorescence microscope. For two-stage efferocytosis experiments, PKH67-labeled ACs were incubated with macrophages for 45 min followed by vigorous rinsing 3 times with 1X PBS. Macrophages were then incubated for another 2 hr, followed by addition of PKH27-labeled ACs. After 45 min, unbound ACs were removed by rinsing, and then the macrophages were fixed with 4% formaldehyde and imaged on an epifluorescence microscope.

Engulfment of IgG-Opsonized sRBCs and Latex Beads

Sheep red blood cells (sRBCs) were opsonized by incubating sRBCs with 1 μ g/ml anti-sRBC antibody for 1.5 hr at 37°C. Opsonized sRBCs or 4- μ m fluorescent beads were incubated with macrophages, and engulfment efficiency was measured as described in the *"in vitro* efferocytosis assay" section. For conjugation of phosphatidylserine to beads, streptavidin-coated 6- μ m beads were incubated with biotinylated phosphatidylserine for 18 hr at 4°C.

Phagosome Sealing Assay

Apoptotic cells or IgG-opsonized sRBCs were labeled with PKH67, and then cell-surface biotinylation was conducted using EZ-link sulfo-NHS-biotin. Cells were suspended in 1X PBS (pH 8.0), incubated with 1 mM biotin for 30 min and then washed 3x with culture

media to remove unbound biotin. These fluorescent and biotinylated cells or biotinylated beads were then added to macrophages for either 15, 30, or 60 min unless otherwise mentioned. At the end of the incubation period, the unengulfed cells were removed by rinsing 3 times in 1X PBS, and the adherent cells were fixed with 2% paraformaldehyde for 10 min followed by 3 rinses with 1X PBS. The cells were then incubated with streptavidin-Alexa fluor 568 for 30 min followed by 3 washes with 1X PBS. Imaging was conducted using an Olympus IX-70 inverted epifluorescence microscope connected to an Olympus DP71 CCD camera. Apoptotic cells or sRBC-containing phagosomes that did not stain positive for streptavidin-Alexa fluor 568 were considered sealed, while ACs or sRBC-containing phagosomes that were positive for streptavidin-Alexa Fluor 568 were considered unsealed.

Time-lapse Imaging of CypHer5E

BMDMs were seeded at a density of 3×10^5 cells per well of a 2-well glass slide. In parallel, neutrophils were isolated from the peritoneal cavity of mice 6 hr following intraperitoneal injection of zymosan (1 mg). The neutrophils were incubated with Hoechst for 30 min to stain nuclei, and after 3 rinses with 1X PBS, the neutrophils were resuspended in 1X PBS and cultured for 12 hr at 37° C to allow spontaneous apoptosis. The apoptotic neutrophils were then labeled with the pH-sensitive dye CypHer5E and incubated with macrophages at an AC:macrophage ratio of 2:1 for 30 min at 4° C. Unbound ACs were removed by rinsing of the macrophage monolayers, and then the slide was placed in a stage-top incubator maintained at 37° C with 5% CO₂. The cells were viewed at 100X magnification on a confocal fluorescence microscope (NIKON A1 Confocal), and images of the same field were recorded at approximately 3.57 min intervals. Sixty separate fields were imaged using this protocol.

Lentivirus Cloning and Production

To target GCaMP6f to the mitochondria, a duplex of the mitochondrial targeting signal of cytochrome *c* oxidase subunit VIII (COX8) was added before the initial ATG of GCaMP6f by replacing the carmine indicator with GCaMP6f in the vector CMV-mito-CAR-GECO1. CK-GCaMP6f and 2x-COX8-GCaMP6f were subcloned into lentiviral transfer vectors and then packaged and concentrated by ALSTEM. The lentiviral transfer vector was cut with Xbal and Notl (NEB) at 37°C for 2 hr. Inserts were amplified by PCR from CK-GCaMP6f and 2x-COX8-GCaMP6f plasmids, digested with Xbal and Notl, and ligated into the lentiviral vector. To make the virus, the lentiviral transfer plasmids were co-transfected with packaging plasmids. Viral supernates were harvested 48 hr after transfection, centrifuged, and filtered through a 0.45- μ m filter (Millipore). Viral particles were pelleted at 50,000 x g at 4°C for 2 hr, resuspended in DMEM, aliquoted, and stored at -80°C. Viral titers were determined by Lenti-X qRT-PCR Titration Kit.

Cytosolic, Mitochondrial, and ER Calcium Measurements

Macrophages were incubated for 18 hr with lentiviruses at an MOI of 5 for GCaMP6f, 2.5 for 2x-COX8-GCaMP6f, and 5 for ER-GCaMP6-150. After 2-3 days, the cells were viewed by live-cell confocal fluorescence microscopy as above after being exposed to CellVue Claret-labeled ACs. Measurements of relative GFP intensity/macrophage, as an indicator of calcium level, were begun when ACs fell into the plane of focus of the macrophages. Images were captured every 5 min.

Analysis of Apoptotic Cell Fragmentation

PKH26- and Hoechst-labeled ACs were added to macrophages for 45 min, and then unengulfed ACs were removed by vigorous rinsing with 1X PBS. After culture for 3 additional hours, the macrophages were fixed with 4% formaldehyde, and images were captured using an epifluorescence microscope. The percent of macrophages containing fragmented AC-derived fluorescence, which is a measure of AC corpse degradation, was quantified.

Vesicular Exocytosis Measurements Using the Styryl Dye FM1-84

Macrophages were incubated with 10 µM FM1-84 in serum-free DMEM for 60 min and then rinsed twice with serum-free DMEM and incubated in this media for an additional 10 min. CypHer5E-labeled apoptotic Jurkat cells were added to the macrophages, and time-lapse imaging was performed, as mentioned previously, with images taken every 1.5 min. Analysis was synchronized between groups based on first appearance of CypHer5E positivity, using fluorescent decay of FM1-84 as an indicator of vesicular exocytosis.

ATP Measurements

Using the ATP detection kit, cells were lysed in the ATP assay buffer (provided in the kit) and centrifuged at maximum speed on a table top microfuge for 2 min. The supernatant fraction was collected and tested for ATP levels by assaying phosphorylation of glycerol, where the readout is generation of a fluorometric product with Ex/Em = 535/587 nm.

ROS Measurements

ROS was detected using the ROS-sensitive fluorescent probe 2',7'-dichlorodihydrofluorescein diacetate (H2-DCFDA). Apoptotic Jurkat cells were loaded with 10 μ M H2-DCFDA for 30 min, rinsed twice, and then added to macrophages for the indicated times. Unbound ACs were removed by rinsing the monolayer, and macrophages were detached with Cellstripper solution and subjected to flow cytometry (BD Canto II) for fluorescence detection. In certain experiments, H2-DCFDA detection was measured on a fluorescence plate reader at Ex/Em = 495/520.

Lysosomal pH Measurements

Lysosomal pH was assayed based on the fluorescence ratio of pH-sensitive fluorescein fluorescence to pH-insensitive rhodamine as follows (Majumdar et al., 2007): the cells were incubated for 16 hr with 2.5 mg/ml dextran conjugated to both fluorescein and rhodamine. After incubation for 4 hr to allow dextran accumulation in the lysosomes, the cells were imaged in a buffer containing 150 mM NaCl, 20 mM HEPES, 1 mM CaCl₂, 5 mM KCl, 1 mM MgCl₂, and 0.2% (w/v) glucose. Images were acquired with a Zeiss LSM 510 laser scanning confocal microscope using a 63X 1.4 numeral aperture objective, and z stacks were analyzed in order to have all lysosomes quantified. Images were analyzed using MetaMorph image analysis software (Molecular Devices), with individual lysosomal fluorescence calculated for the ratio of fluorescein to rhodamine fluorescence. Calibration curves were generated after fixing and equilibrating the fluorescein-rhodamine-dextran-loaded cells to a range of pH buffers.

Immunoblotting

Cells were lysed in 2X Laemmli sample buffer containing 50 mM DTT and heated at 100°C for 10 min. Lysates were separated on 4%–20% gradient SDS-PAGE gels at 120-150V for 1.5-2 hr, electro-transferred to 0.45-µm nitrocellulose or PVDF membranes at 100V for 2 hr, incubated overnight at 4°C with primary antibodies in either 1X PBS containing 1% BSA or TBST containing 5% non-fat dry milk, and detected using HRP-conjugated secondary antibodies. Densitometry was performed using ImageJ software.

siRNA-Mediated Gene Silencing

Scrambled siRNA control and oligo-targeting siRNAs were transfected into macrophages using Lipofectamine 2000 or Lipofectamine RNAiMax (Life Technologies) at 20-50 nM of siRNA in 24-well plates. Macrophages were incubated for 18 hr with in Opti-MEM containing 3 μ L Lipofectamine 2000 or 1.5 μ L Lipofectamine RNAiMAX per 0.2 × 10⁶ cells and 20-50 nM siRNA. Experiments and mRNA analyses were conducted 2-3 days later.

Quantitative RT-PCR

RNA was extracted from samples using the RNeasy Micro Kit. The purity of the RNA was assessed by absorbance at 260 and 280 nm using a Thermo Scientific NanoDrop spectrophotometer. Using RNA with a 260/280 ratio of > 1.8, cDNA was synthesized using oligo (dT) and Superscript II. Quantitative RT-PCR was performed using a 7500 Real-Time PCR system (Applied Biosystems) and SYBR Green Master Mix.

Immunocytochemistry

Macrophages were either fixed with ice-cold acetone on ice for 5 min or with 4% formaldehyde for 10-15 min. After three rinses with 1X PBS, the cells were either directly incubated with blocking buffer (1X PBS with 10% serum and 1% BSA) for 1 hr or permeabilized with 0.1% Triton for 10 min, or with 50 μ g/ml of digitonin for 5 min for LC3 staining, and then incubated with blocking buffer for 1 hr. The cells were then incubated overnight at 4°C with antibodies against Drp1 (1:200 dilution), COX IV (1:200 dilution), or LC3 (1:100 dilution), followed by incubation with Alexa Fluor-conjugated antibodies for at least 2 hr. Excess antibody was removed by rinsing 3 times with 1X PBS, and the cells were viewed by confocal fluorescence microscopy (NIKON A1 Confocal).

Tissue Collection and Lesion Analysis

For atherosclerosis studies, $Drp1^{fl/fl}$ mice were generated as previously described (Ishihara et al., 2009) and backcrossed for a minimum of ten times onto the C57BL/6J background. The mice were genotyped using a Drp1 primer that targeted exon 2, which is flanked by two *Loxp* sites. These mice were bred with C57BL/6J *Ldlr^{-/-}* mice from Jackson Laboratories and then crossed with C57BL/6J LysMCre mice to delete Drp1 in myeloid cells (Clausen et al., 1999). Eight-to-ten-week-old $Drp1^{fl/fl} Ldlr^{-/-}$ Lysmcre^{-/-} or $Drp1^{fl/fl} Ldlr^{-/-}$ Lysmcre^{+/-} male mice were placed on a high-fat Western Diet for 12 weeks before euthanasia. Immediately after sacrifice, mice were perfused with 1X PBS by cardiac puncture in the left ventricle, and aortic roots were collected and processed for cryosectioning. For morphometric lesion analysis, sections were stained with hematoxylin and eosin. Total intimal lesion area from internal elastic lamina to the lumen and acellular necrotic areas, which are areas negative for hematoxylin-positive nuclei, were quantified by taking the average of 6 sections spaced 30 μ m apart, beginning at the base of the aortic root. Boundary lines were drawn around these regions, and the area measurements were obtained by image analysis software. A 3,000- μ m² threshold cut-off for acellular areas was used to quantify areas of necrosis. Fasting blood glucose levels were measured using ONETOUCH Ultra after food was withdrawn for 5-6 hr. Total plasma cholesterol, HDL-cholesterol, and triglyceride were measured using kits from WAKO Diagnostics. Pooled plasma from 3 mice per cohort were fractionated by FPLC gel filtration using a Superose 6 column (Amersham Pharmacia) at a flow rate of 0.2 ml/minute, followed by cholesterol assay of the fractions.

In Vivo Thymus Efferocytosis Assay

Eight-week-old female mice were injected i.p. with 200 µl PBS containing 250 µg dexamethasone dissolved in DMSO. Eighteen hours after injection, the mice were euthanized and thymuses were harvested. Thymus cellularity was quantified by mechanically disaggregating a lobe of the thymus and then counting cells using a hemocytometer. Another aliquot of cells was fixed in 4% paraformaldehyde for 15 min, permeabilized with 0.1% Triton for 8 min, washed with PBS, incubated with TUNEL staining reagents, and analyzed by flow cytometry to determine the number of TUNEL-positive cells. The other thymus lobe was formalin-fixed and

paraffin-embedded and sectioned, followed by staining of the sections (5 μ m) with TUNEL reagent and antibody to F4/80 and then fluorescent secondary antibody to immunostain macrophages. Images were captured using a Leica epifluorescence microscope (DMI6000B). For the $Mcu^{-/-}$ bone marrow transplantation experiment, 10-week-old male CD-1 recipient mice were given acidic water containing neomycin and polymyxin B (10 mL of 10 mg/ml neomycin in saline and 400 mL of 25 mg/ml polymyxin B sulfate in water added to 1 I of acidic water) one week before irradiation. The mice were then irradiated using 1000 rads from a 137 Cesium Gammacell source. Four hours after irradiation, the mice were injected via tail vein with 5 × 10⁶ bone marrow cells from 16-20-week-old wild-type (WT) CD-1 mice or $Mcu^{-/-}$ CD1 male mice (Pan et al., 2013). The bone marrow cells were prepared as follows: Femurs from donor mice were isolated and flushed with RPMI 1640, supplemented with heat-inactivated FBS (2% vol/vol), 10 units/ml of heparin, and a cocktail of 10 U/mL penicillin and 100 μ g/mL streptomycin. The cells were filtered through a 40- μ m nylon cell and centrifuged at 2000 rpm for 10 min at 4°C. Bone marrow cells were rinsed and pelleted twice more. Six weeks after injection of bone marrow cells, the mice were subjected to the dexamethasone procedure and efferocytosis analysis as outlined above. For confirmation of successful transplantation, whole splenic cells were immunoblotted for MCU and β -actin.

Immunohistochemistry and Immunofluorescence Microscopy

Frozen specimens were immersed in OCT and cryosectioned, and 6-μm sections were placed on glass slides and then exposed to ice-cold acetone for 10 min to fix and permeabilize. Paraffin-embedded specimens were sectioned, de-paraffinized with xylene, and rehydrated in decreasing concentrations of ethanol. Sections were incubated with TUNEL staining reagents at 37°C for 60 min, and then washed 3 times with 1X PBS. Sections were then blocked with 10% goat serum for 30 min, incubated overnight at 4°C with anti-Mac3 (1:200) or F4/80 (1:200), incubated with fluorescently-labeled secondary antibodies, and counterstained with DAPI. In situ efferocytosis was quantified by counting TUNEL-positive nuclei that were associated with macrophages ("associated"), indicative of efferocytosis, or not associated with macrophages ('free'). Macrophage-associated apoptotic cells followed the criteria of TUNEL-positive nuclei surrounded by or in contact with neighboring F4/80+ macrophages. Free apoptotic cells exhibited nuclear condensation, loss of antibody F4/80 reactivity, and were not in contact with neighboring macrophages.

QUANTIFICATION AND STATISTICAL ANALYSIS

Data were tested for normality using the Kolmogorov-Smirnov test, and statistical significance was determined using GraphPad Prism software. Data that passed the normality were analyzed using Student's t test for two groups with one variable tested and equal variances, one-way ANOVA with Newman-Keuls post-test for multiple groups with only variable tested, or two-way ANOVA with Bonferroni post-tests for more than two groups with multiple variables tested. Data that were not normally distributed but contained equal variances were analyzed using the nonparametric Mann-Whitney U test with post hoc analysis. Data are shown as mean values \pm SEM. Differences were considered statistically significant at p < 0.05.

Supplemental Figures



Figure S1. Interaction of Macrophages with Apoptotic Cells Leads to an Increase in Drp1, which Promotes Efferocytosis, Related to Figures 1 and 2

(A) $Cre^{-/-}$ and $Cre^{+/-}$ bone marrow-derived macrophages were rendered apoptotic by treatment with 35 μ M 7-ketocholesterol and then incubated with WT bone marrow-derived macrophages at a ratio of 10:1 for 45 min. The unengulfed ACs were removed by rinsing, and whole cell lysates were immunoblotted for Drp1 and β -actin. The bar graph shows densitometric quantification of immunoblots normalized to β -actin (n = 3 biological replicates).

(B) Cre^{-/-} and Cre^{+/-} peritoneal macrophages were assayed for *Drp1* mRNA relative to *Actb* by RT-QPCR (n = 3 biological replicates).

⁽C) Total cells lysates of $Cre^{-/-}$ and $Cre^{+/-}$ peritoneal and bone marrow (BM)-derived macrophages were immunoblotted for Drp1 and two mitochondrial proteins, PDH1 α and VDAC1.

⁽D) Cre^{-/-} and Cre^{+/-} bone marrow-derived macrophages were incubated with or without apoptotic Jurkat cells for 45 min, and then lysates were immunoblotted for Drp1.

⁽E) Cre^{-/-} and Cre^{+/-} peritoneal macrophages were immunostained using antibodies against Drp1 (green) and the mitochondria marker cytochrome C oxidase IV (COX IV) and viewed by confocal microscopy. Bar, 1 μm.

⁽F) Cre^{+/-} bone marrow-derived macrophages were rendered apoptotic by treatment with 35 µM 7-ketocholesterol and then incubated with WT bone marrowderived macrophages at a ratio of 10:1 for 15 or 45 min. The unengulfed ACs were removed by rinsing, then cells were collected and assayed for Drp1 mRNA relative to Actb by RT-QPCR (n=3 technical replicates).

⁽G) Bone marrow-derived macrophages were treated for 30 min with 1 μ g/ml actinomycin D or 10 μ g/ml cycloheximide then incubated with or without apoptotic Jurkat cells for 45 min. Lysates were immunoblotted for Drp1 and β -actin. The bar graph shows densitometric quantification of immunoblots normalized to β -actin (n = 4 biological replicates).

⁽H) CypHer5E-labeled apoptotic Jurkat cells were incubated with PKH67-labeled macrophages at 10:1 ratio for 45 min. The unengulfed ACs were removed by rinsing, and the macrophages were detached from the plate for flow cytometric analysis of CypHer5E⁺ PKH67⁺ cells, which reflects efferocytosis. Representative contour plots and quantified data are shown (n = 3 biological replicates).

⁽I) Macrophages were treated with 10 μ M MDIVI-1 or vehicle control, and then the cells were incubated with PKH26-labeled apoptotic Jurkat cells were for 1 hr at a 10:1 AC:macrophage ratio (left) or for 2 hr at a 5:1 AC:macrophage ratio (right). Efferocytosis was measured as the total percent of macrophages positive for PKH67-labeled ACs (n = 4 biological replicates).





(A) Macrophages differentiated from bone marrow cells of Cre^{-/-} and Cre^{+/-} mice were analyzed by flow cytometry for cell-surface F4/80, CD68, and FcγRI. Average MFI per macrophage is shown (n = 3 biological replicates).

(B and C) Cre^{-/-} and Cre^{+/-} bone marrow-derived macrophages were treated with LPS and IFN_γ or with IL-4 and then assayed for *Nos2*, *Tnfa*, *II6*, *Arg1*, *Mrc1*, and *Retnla* mRNA by RT-qPCR, with normalization to 36B4 (n = 3 biological replicates).

For all panels, values are mean + S.E.M.; *p < 0.05; n.s., not significant.

⁽D) Macrophages were treated with vehicle control or 10 μ M MDIVI-1 followed by incubation with PKH67-labeled apoptotic Jurkat cells for 45 min at a 5:1 AC:macrophage ratio. Unengulfed cells were rinsed away, and, a after a 2 hr incubation period, the macrophages were labeled with MitoTracker Red FM and incubated for 45 min with CellVue Claret-labeled ACs at a 5:1 AC:macrophage ratio. Macrophages that had not engulfed an AC or engulfed 2 ACs were visualized by confocal microscopy and quantified for average mitochondrial length (n = 3 biological replicates with 10 cells per treatment group quantified). (E) Vehicle-treated Cre^{-/-} and Cre^{+/-} macrophages or MDIVI-1-treated Cre+/- macrophages were subjected to the two-stage efferocytosis assay described in Figure 2C (n = 4 biological replicates).





(A) Macrophages transfected with scrambled RNA or *Mff* siRNA were incubated with PKH67-labeled apoptotic Jurkat cells and MitoTracker Red FM for 45 min at a 5:1 AC:macrophage ratio. Macrophages that had or had not engulfed an AC (AC⁺, AC⁻) were visualized by confocal microscopy. Mean mitochondrial length was measured in 0.5 μ m z sections in at least 10 cells per group across four biological replicates (n = 3 with \geq 10 cells quantified per group). Also shown is an immunoblot of Mff in ScrRNA- and *Mff* siRNA-treated macrophages.

(B) Macrophages treated with ScrRNA or Mff siRNA were subjected to the two-stage efferocytosis assay described in Figure 2C.

Values are mean \pm S.E.M.; *p < 0.05; n.s., not significant.

⁽C) Macrophages treated with ScrRNA or *Mfn1* siRNA were immunoblotted for Mfn1, Drp1, and β -actin (n = 3 biological replicates).

⁽D) Macrophages treated with ScrRNA, Drp1 siRNA, or Mfn1 siRNA were immunostained using an antibody against the mitochondria marker, ATP5A, and viewed by confocal microscopy. Bar, 1 μ m.

⁽E) Macrophages treated with ScrRNA, *Mfn1* siRNA, or *Drp1* siRNA were incubated for 1 hr with PKH67-labeled apoptotic Jurkat cells at a 10:1 AC:macrophage ratio and then efferocytosis was measured. The data are quantified as percent of macrophages positive for PKH67-labeled ACs (n = 3 biological replicates). (F) Macrophages treated with ScrRNA or *Mff* siRNA were subjected to the phagosome sealing assay after 45 min of incubation with ACs, as described in Figure 3

⁽n = 4 biological replicates).

⁽G) Images from the time-lapse fluorescence microscopy experiment in Figure 3B examining time to CypHer5E positivity. Arrows in 0 min images show the AC being monitored. Bar, 5 µm.

⁽H) $Cre^{-/-}$ and $Cre^{+/-}$ macrophages were incubated for 16 hr with dual-labeled rhodamine and fluorescein dextran to label lysosomes. Lysosomal pH was determined by analyzing the fluorescein/rhodamine ratio (n = 3 biological replicates with 30 cells per group quantified per experiment).

⁽I) $Cre^{-/-}$ and $Cre^{+/-}$ macrophages were subjected to the two-stage phagocytosis assay described in Figure 2C, using biotinylated versions of the indicated particles instead of biotinylated ACs (n = 3 biological replicates).



Figure S4. Drp1-Deficient Macrophages Have Defects in AC Corpse Degradation and Phagosomal ROS, Quantification of ATP, and Illustrative Images of GCaMP6f Fluorescence Over Time, Related to Figures 4 and 5

(A) Time-lapse confocal fluorescence microscopy of $Cre^{-/-}$ and $Cre^{+/-}$ macrophages incubated with apoptotic PMNs labeled with CypHer5E. Time to AC fragmentation was quantified as the time interval between the first frame in which the AC became CypHer5E + (t = 0 min) and the frame in which there was the first evidence of fragmentation of the CypHer5E signal (arrows). The time interval between each frame was \sim 3.57 min, some of which are displayed here. Bar, 10 μ m. The bar graph shows the mean ± S.E.M., *p < 0.0001 (n = 15 cells per group).

⁽B) Cre^{-/-} and Cre^{+/-} macrophages were treated with 200 nM rapamycin (Rap) or vehicle control (Veh) for 18 hr. The cells were then fixed with 2% paraformaldehyde, permeabilized with digitonin, and immunostained for LC3. Fluorescence microscopic analysis was conducted to quantify the average number of LC3+ punctae (red spots) per cell (n = 200 cells per group).

⁽C) $Cre^{-/-}$ and $Cre^{+/-}$ macrophages were incubated for 45 min with H2DCFDA-labeled apoptotic Jurkat cells that were loaded with the oxidant, TBHP (50 μ M), or vehicle control. Unengulfed ACs were then removed by rinsing, and the macrophages were then assayed for H2DCFDA fluorescence as a measure of ROS (n = 3 biological replicates).

For panels B-C, values are mean ± S.E.M.; *p < 0.05; n.s., not significant.

⁽D) Cre^{-/-} and Cre^{+/-} macrophages were incubated for 45 min under control conditions (no ACs) or with ACs, and relative ATP levels were quantified using an ATP fluorescence assay (n = 3 technical replicates).

⁽E–G) Images from the time-lapse fluorescence microscopy experiment in Figures 5A and 5B examining Cyto- and Mito-GCaMP6f fluorescence intensity over time in AC- and AC+ $Cre^{-/-}$ and $Cre^{+/-}$ macrophages; and images and quantified data for a similar experiment using ER-GCaMP6f-150 (n = 3 cells for AC⁻ macrophages and n = 10 cells for AC⁺ macrophages, with 2 plates of cells examined for each condition; values are mean \pm S.E.M, *p < 0.05 for the two AC⁺ groups relative to the two AC⁻ groups, with no significant difference between the $Cre^{-/-}$ and $Cre^{+/-}$ groups). Bars, 10 μ m.



Figure S5. Control Experiment-Related Calcium Dynamics and Lysosome Acidification and Summary of Pathway, Related to Figures 5 and 6 (A) Wild-type macrophages were treated with 5 μ M BAPTA-AM, and membrane-bound LC3 MFI was quantified by flow cytometry as in Figure 4C (n = 3 biological replicates).

(B) Cre^{-/-} and Cre^{+/-} macrophages were incubated with 2 µM ionomycin (lono) or vehicle control (Veh), and membrane-bound LC3 MFI was quantified by flow cytometry as in Figure 4C (n = 4 biological replicates).

(C) Immunoblot of MCU1 and β-actin from macrophages incubated for 45 min without or with apoptotic Jurkat cells (ACs) (n = 3 biological replicates).

For all panels, values are mean \pm S.E.M.; *p < 0.05; n.s, not significant.

⁽D) $Cre^{-/-}$ and $Cre^{+/-}$ macrophages were transfected with scrambled RNA or *Mcu* siRNA and then incubated for 45 min with PKH67-labeled apoptotic Jurkat cells and MitoTracker Red FM at a 5:1 AC:macrophage ratio. Mitochondrial length was length measured as in Figure 1 (n = 10 cells analyzed per group). (E) WT macrophages were treated with 1 μ M bafilomycin (Baf) or vehicle control (Veh), incubated with PKH67-labeled ACs, and then assayed for mitochondrial

⁽E) W1 macrophages were treated with 1 µM batilomycin (Bat) or venicle control (Ven), incubated with PKH67-labeled ACs, and then assayed for mitochondria length in macrophages containing or not containing ACs (n = 3 biological replicates).

⁽F) Control and bafilomycin-treated macrophages were incubated with biotinylated ACs for the indicated times and then subjected to the phagosome sealing assay described in Figure 3 (n = 3 replicates for each time point).

⁽G) Proposed model linking mitochondrial fission in macrophages engaging an AC to high-burden efferocytosis.





Figure S6. Quantification of Apoptotic Cells and Cytokine mRNAs in the Thymuses of Dexamethasone-Treated Mice and Validation of $Mcu^{-/-}$ and MDIVI-1-Treated Mice, Related to Figure 7

(A) Representative images of thymuses from Cre^{-/-} and Cre^{+/-} mice 18 hr after i.p. injection of PBS or 250 µg dexamethasone. Bar, 1 mm.

(B) Thymocytes from $Cre^{-/-}$ and $Cre^{+/-}$ mice were treated with PBS or 100 μ M dexamethasone for 2 hr then stained with Annexin V and analyzed for the percentage of annexin V⁺ cells by flow cytometry (n = 4 biological replicates per group).

(C) The thymuses of dexamethasone-treated Cre^{-/-} and Cre^{+/-} mice were assayed for the indicated mRNAs by RT-qPCR and expressed as fold-change relative to the Cre^{-/-} value (n = 4 mice per group).

(G) Thymocytes from $Cre^{-/-}$ mice were incubated for 2 hr with 100 μ M dexamethasone or vehicle control with or without 10 μ M MDIVI-1. The cells were then stained with annexin V and analyzed for the percentage of annexin V⁺ cells by flow cytometry (n = 3 biological replicates). For all panels, values are mean \pm S.E.M.; *p < 0.05; n.s., not significant.

⁽D) The thymuses of dexamethasone-treated $Cre^{-/-}$ and $Cre^{+/-}$ mice were surface-immunostained for F4/80 and assayed for F4/80+ cells by flow cytometry (n = 8 mice per group).

⁽E) Irradiated WT CD1 mice were transplanted with bone marrow from WT CD1 mice or $Mcu^{-/-}$ mice on the CD1 background. After 6 weeks, the mice were sacrificed, and spleen lysates were immunoblotted for MCU and β -actin.

⁽F) $Cre^{-/-}$ and $Cre^{+/-}$ mice were injected i.p. every 12 hr for 3 treatments with 20 mg/kg MDIVI-1 or vehicle control. Macrophages were isolated from the thymuses of the mice in (C) and then fixed, immunostained stained for COXIV, and viewed by confocal fluorescence microscopy. Bar, 5 μ m. Average mitochondrial length was measured in ≥ 10 cells per group across three biological replicates.







(A) Aortic smooth muscle cells isolated from Cre^{-/-} and Cre^{+/-} mice were assayed for *Drp1* mRNA relative to *Actb* by RT-QPCR (n = 3 biological replicates). (B–F) Body weight, fasting blood glucose, plasma cholesterol, triglyceride levels, and plasma lipoprotein profile from 12-week WD-fed *Drp1*^{t/fl} *Lysmcre*^{+/-} (Cre^{-/-}) and *Drp1*^{t/fl} *Lysmcre*^{+/-} (Cre^{+/-}) mice on the *Ldlr*^{-/-} (LDLR-KO) background.

(G) Aortic root cross-sections of 12-week WD-fed mice were quantified for total lesion area and immunostained for Mac3, followed by analysis of Mac3+ cells/ section (n = 12-14 mice per group).

(H) Peritoneal macrophages from $Cre^{-/-}$ and $Cre^{+/-}$ mice were treated for 24 hr with vehicle (Veh), 50 µg/ml oxidized LDL (oxLDL), or 35 µg/ml 7-ketocholesterol (7-KC). The cells were then stained with Annexin V and analyzed for the percentage of annexin V⁺ cells by flow cytometry (n = 3 replicates per group). For all panels, values are mean \pm S.E.M.; *p < 0.05; n.s., not significant.